Клинико-иммуноцитохимическая характеристика и прогнозирование опухолевой прогрессии неходжкинских злокачественных лимфом
Диссертация
Результаты данного исследования могут быть использованы в практике работы иммуноморфологических лабораторий, поскольку предоставляют новые возможности для решения задач прогностический оценки прогрессии лимфом и дифференциальной диагностики фолликулярной и лимфо-плазмоцитарной лимфомы с другими вариантами В-НХЗЛ, имеющими схожие морфологические характеристики, а также для выделения трех… Читать ещё >
Список литературы
- Анемический синдром у больных лимфопролиферативными заболеваниями: патогенез и новые возможности коррекции./ А. С. Лямкина, Т. И. Поспелова, М. И. Лосева и др. // Журнал клинической и экспериментальной медицины. 2004.- № 1−2.-С.171−177.
- Аспартильные протеиназы: их роль при опухолевом росте и влияние противоопухолевой терапии / О. В. Фаламеева, Т. А. Короленко, С. Я. Жанаева, В. И. Каледин // Бюл. СО РАМН. 2001. — N 1. — С. 37−40.
- Борисевич Н. В. Иммунологическая характеристика первых рецидивов острого лимфобластного лейкоза у детей и оценка эволюции иммунофенотипа бластных клеток в рецидиве./Н.В.Борисевич, М. В. Белевцев, О. В. Алейникова// Гем и транс.-2004.- № 2.-С.14−17.
- Боровиков В.П. Прогнозирование в системе STATISTIC, А в среде Windows: основы теории и интенсивная практика на компьютере: учебное пособие./ В. П. Боровиков, Г. И. Ивченко.- 2-е изд., перераб и доп.-М.:Финансы и статистика, 2006.-368с.
- Боровиков В.П. Популярное введение в программу STATISTIC, А / Боровиков В.П.-М.Финансы и статистика, 2000.-267с.
- Боровиков В.П. Программа STATISTICA для инженеров и студентов./ Боровиков В.П.-М.:Финансы и статистика, 2001.- 300с.
- Влияние некоторых цитокинов на клинико-морфологические особенности неходжкинских злокачественных лимфом /Т.И.Поспелова, М. И. Лосева, Н. В. Скворцова и др./Журнал клинической и экспериментальной медицины // 2005.- № 4.- С.203−211.
- Воробьев А.И. Руководство по гематологии: в 2 т./под ред А. И. Воробьева.-М.:Ньюдиамед, 2003.-Т.2.-277с.
- Воробьев А.И. Руководство по гематологии: в 2 т./под ред И. И. Воробьева.-М.:Ньюдиамед, 2003.-Т.1.-148с.
- Ю.Воробьев А. И., Бриллиант М. Д. Нелейкемические гемобластозы./ Руководство по гематологии/ под ред. А. И. Воробьева.-М.: Медицина, 1985.-Т.1.-С.315−351.
- Высокая апоптогенная и противоопухолевая активности продуктов биологической, но не химической активации циклофосфомида./ В. И. Каледин,
- B.П.Николин, М. Р. Галямова и др.// Докл. акад.наук.-2000.-том 386.-№ 5.1. C.705−708.
- Гублер Е.В. Вычислительные методы анализа и распознавания патологических процессо ./ Е. В. Гублер.-Л.:Медицина. 1978. — 293 с.
- Гублер Е.В. Информатика в патологии, клинической медицине и педиатрии /Е.В. Гублер.-Л.Медицина. 1990. -176 с.
- Демина Е.А. Современная терапия первичных больных лимфомой Ходжкина:автореф.дис. .доктора.мед.наук: 14.00.14/Е.А.Демина-РС)НЦ им. Н. Н. Блохина.-Москва, 2006.-46с.
- Денисова В.В. Морфофункциональная характеристика клеток эритроидного ряда у больных лимфомами при проведении химиотерапии: автореф. дис.канд.мед.наук: 14.00.36 /В.В.Денисова -НИИ клинической иммунологии СО РАМН.-Новосибирск, 2004.-18с.
- Динамическое исследование реаранжировки генов иммуноглобулинов и Т-клеточных рецепторов при острых лимфобластных лейкозах./ Ю. Р. Давидян, В. Л. Сурин, Е. Н. Паровичникова, В. Г. Савченко//Гем и транс.-2006.- № 2.-С.З-10
- Зайцев В.М. Прикладная медицинская статистика: учебное пособие./В.М.Зайцев, В. Г. Лифляндский, В. И. Маринкин.-СПб. .ФОЛИАНТ, 2002. 429с.
- Значение иммуноморфологических маркеров апоптоза при оценке опухолевой прогрессии лимфобластной неходжкинской лимфомы./ И. Б. Ковынев, Т. И. Поспелова, М. И. Лосева и др.//Журнал клинической и экспериментальной медицины.-2004, — № 1−2.-С. 190−195.
- Изучение экспрессии дифференцировочных антигенов лимфопоэза на мембране мононуклеаров периферической крови при опухолевой прогрессии лимфосарком./И.А.Лисуков, И. Б. Ковынев, М. И. Лосева и др. // Тер.архив.-1991 .-№ 7.-т.63 .-С.78−80.
- Иммуногенетические маркеры гемобластозов./Ю. М. Зарецкая, Е. Г. Хамаганова, С. М. Алещенко и др.//Тер.архив.- 2000.-№ 12.-С.54−58.
- Иммунологический фенотип лейкозной клетки./Ф.Ю.Барышников, З. Т. Кагаидзе, Л. А. Махонова, Н. Н. Тупицин М.:Медицина.-1989.-230с.
- Иммуноморфологические варианты лимфобластных неходжкинских лимфом у взрослых и детей. /И.Б.Ковынев, М. И. Лосева, Т. И. Поспелова и др. //Вест. гемат.-2006.-том 2,№ 3.-С.16−21.
- Иммунофенотип бластных клеток при остром Т-клеточном лимфобластном лейкозе у детей / Н. А. Торубарова, Е. Л. Семикина, Е. А. Копыльцова и др. // Гем и транс.- 2005 .-№ 5.-С.З-9.
- Иммунофенотипирование опухолей системы крови и лимфатических опухолей Часть I. Зрелоклеточные лимфомы и лимфосаркомы./И. А. Воробьев, О. А. Худолеева, Т. Д. Рощупкина и др.// Гем и транс.- 2005 .-№ 1.-С.7−13.
- Иммунофенотипирование опухолей системы крови и лимфатических опухолей. Часть II. Острые лейкозы./И. А. Воробьев, О. А. Худолеева, Т. Д. Рощупкина и др.// Гем и транс.- 2005 .-№ 3.-С.8−15.
- Индивидуальная вариабельность и клиническое значение плотности иммунофенотипических маркеров В-клеточного хронического лимфолейкоза./Е. И. Селиванова, Ю. Е. Виноградова, И. А. Замулаева и др.// Гем и транс.- 2005 .-№ 3.-С.25−29.
- Козяева Е.В. Человеческий потенциал: социально-медицинские аспекты: Учеб. пособие / Е. В. Козяева, И. В. Мегрелидзе. М., 2005. — 30с.
- Количественные и функциональные характеристики Т-лимфоцитов и моноцитов у пациентов лимфосаркомой на различных стадиях опухолевого процесса./М.И.Лосева, И. Б. Ковынев, В. С. Ширинский и др.//Гематол. и трансфузиол.-1993, ноя-дек.-№ 38(9).-С.З-5.
- Криволапов Ю.А. Результаты гистологических и иммуногистохими-ческих исследований первичных биопсий у 400 больных с поп-Нос^ш'э лимфомой в Северо-Западном регионе России./Ю.А.Криволапов// Тер арх.-2004-№ 76.-том 7.-С.64−70.
- Криволапов Ю.А. Морфологическая диагностика лимфом./ Ю. А. Криволапов, У. У. Леенман.- СПб.:"КОСТАи, 2006.-208с.
- Левина О. А. Активность и концентрация катепсина В как прогностический фактор при развитии мышиной лимфосаркомы ЬБ и аденокарциномы легких Льюис./Бюл. эксперим. биологии и медицины.- 2002.-Т.133.- № 4.- С. 452−455.
- Лисуков И.А. Иммунологические аспекты множественной миеломы. / Новосибирск: Наука.-2003.-159с.
- Лисуков И.А. Иммунологические критерии прогноза опухолевой прогрессии неходжкинских злокачественных лимфом / И. А. Лисуков // Бюл. СО РАМН. 1998. — N 2. — С. 65−71
- Лисуков И.А. Нарушение процессов пролиферации и дифференцировки стволовой кроветворной клетки при лейкозогенезе: автореф. дис. .канд.мед.наук: 14.00.29/И.А.Лисуков-Новосиб.гос.мед.институт.-Новосибирск, 1988.-210с.
- Лорие Ю.Ю. Опухолевая прогрессия и вопросы биологии лимфогранулематоза. /Ю. Ю. Лорие// Тер.архив.- 2000.-№ 7.-С.76−80.
- Лорие Ю.Ю. Лимфома из клеток мантийной зоны: клинические особенности и возможности терапии./Ю.Ю. Лорие//0нкогематология.-2006.-т.8.-№ 1.-С.56−59.
- Ломакин М.С. Иммунобиологический надзор./ М. С. Ломакин.-М.: Медицина.-1990.-230с.
- Лосева М.И. Клинико-морфологические и биохимические аспектв опухолевой прогрессии в патогенезе лимфогранулематоза: дис.. д-ра мед наук /М.И. Лосева-Новосибир.мед.ин-т.- Новосибирск,-!973.- 350с.
- Лушников Е.Ф. Гибель клетки (апоптоз) / Е. Ф. Лушников, Ф. Ю. Абросимов. -М.'.Медицина, 2001 .-192с.
- Мазуров В.И. Классификация лимфом. Морфология, иммунофенотип, молекулярная генетика неходжкинских лимфом./ В. И. Мазуров, Ю. А. Криволапов //Практ.онкогематология.-2004.-Т.5,№ 3.-С. 166−175.
- Методология иммуноморфологического диагноза в онкогематологической и онкологической клинике./ И. Б. Ковынев, Т. А. Агеева, М. И. Лосева и др.//Тез. докл. междунар. Российско-Норвежской конференции гематологов/ С-Пб, 2003.- С. 74.
- Мониторинг уровня экспрессии гена MDR1 у онкогематологических больных./А.Н.Зенков, Е. Л. Черноловская, М. И. Лосева и др. //Проблемы гематологии.-2002.-№ 1.- С.31
- Морфологические особенности вторичного миелодиспластического синдрома у больных гемобластозами./ Н. Ю. Дьячкова, М. И. Лосева, И. Б. Ковынев и др. //Сборник тезисов международной Российско-Норвежской конференции гематологов.- С-Пб, 2003.- С.68
- Морфологические особенности вторичного миелодиспластического синдрома у больных гемобластозами в динамике полихимиотерапии. / Н. Ю. Дьячкова, М. И. Лосева, И. Б. Ковынев и др.// Журнал клинической и экспериментальной медицины/ 2004.- № 1−2.-С.72−78
- Новик A.A. Современная концепция классификации лимфоидных опухолей / A.A. Новик //Клиническая онкология и гематология. 2001.- № 3.-С.2−9.
- Новиков B.C. Программированная клеточная гибель/В.С. Новиков.-СПб. :Наука, 1996.-276с.
- Олейник Е. К. Маркеры активации лимфоцитов крови (CD25, CD71, CD95 и HLA-DR) у онкологических больных./Е. К. Олейник, М. И. Шибаев, В. М. Олейник//Гем и транс.-2006.- № 1.-С. 18−23.
- Олейник Е. К. Система апоптоза Fas-FasL в онкогенезе./Е. К. Олейник, М. Ю. Донников, В. М. Олейник// Иммунол.- 2004.-№ 4.-С.251−255.
- Определение экспрессии онкобелков р53 и Вс1−2 при лимфогранулематозе иммуногистохимическим методом./ К. Д. Капланов, В. Б. Писарев, Е. П. Корнева и др.//Гем и транс.- 2004 .-№ 2.- С.3−11.
- Основы опухолевой прогрессии гемобластозов. / Т. И. Поспелова, М. И. Лосева, И. Б. Ковынев, Т. А. Агеева и др. // Бюл. СО РАМН 2004. — № 2. -С. 73−76
- Особенности частоты и структуры неходжкинских злокачественных лимфом в Новосибирске, НСО и городах Сибирского федерального округа./И.Б. Ковынев, Т. И. Поспелова, М. И. Лосева и др.//Бюллетень СО РАМН.-2006.-№ 4 (122).-С.175−181.
- Особенности цитокинового статуса у больных неходжкинскими лимфомами./Н.В.Скворцова, Т. И. Поспелова, М. И. Лосева и др. //Журнал клинической и экспериментальной медицины.-2004.- № 1−2.-С.62−72.
- Особенности иммуноморфологической диагностики лимфобластных неходжкинских лимфом./И.Б.Ковынев, М. И. Лосева, Т. И. Поспелова и др. // Вест. НГУ.-2006.-ТОМ 4, вып.З.-С. 15−22.
- Петри А. Наглядная статистика в медицине: пер. с англ./А.Петри, К.Сэбин.-М.:Гоэтар-Мед, 2003.-142с.
- Петров C.B. Руководство по иммуногистохимической диагностике опухолей человека./ под ред.С. И. Петрова и Н. Т. Райхлина.-Казань, 2004.-456с.
- И.В.Поддубная Обоснование лечебной тактики при неходжкиских лимфомах. /Онкогематология (современные аспекты)/ под ред. И. В. Поддубной. -М.:Медиа Медика, 2005.- 204 с.
- Поддубная И.В. Неходжкинские лимфомы / Клиническая онкогематология: руководство для врачей/ под ред.М. А. Волковой.-М. ?Медицина, 2001.-С.336−375.
- Поддубная И.В. Лечение индолентных неходжкинских лимфом./ И.В.Поддубная// Практ.онкогематология.-2004.-Т.5,№ 3.-С.203−208.
- Поддубная И.В. Диагностика и определение распространенности (стадирование) неходжкинских лимфом./ И. В. Поддубная, Е. А. Демина //Практ.онкогематология.-2004.-Т.5,№ 3.-С. 176−184.
- Пожарисский K.M. Значение имммуногистохимических методик для определния характера лечения и прогноза опухолевых заболеваний./К.М.Пожарисский, Е. Е. Леенман // Арх. патол.-2000.-вып.62.-№ 5.-С.З-6.
- Иммунология: в Зт. пер с англ./под ред. У. Пола-М.:Мир, 1989.- Т.359с.
- Пробатова H.A. Морфологические критерии диагностики злокачественных лимфом./ Клиническая онкогематология: руководство для врачей/ под ред.М. А. Волковой.- М."Медицина, 2001.-С.301−312.
- Пробатова H.A. Основные принципы и диагностические критерии пересмотра Европейско-Американской классификации лимфоидных опухолей./ Н. А. Пробатова, Н. Н. Тупицин, Е.В.Флейшман//Арх. патол.-1998.-Т.60.-С.61−71.
- Прогностическое значение очагового поражения костного мозга при диффузной В-крупноклеточной лимфосаркоме./А.У.Магомедова, A.M. Кременецкая, И. А. Воробьев и др. // Тер.архив.- 2004.-№ 7.-С.60−64.
- Продукция негативных регуляторов гемопоэза эритроидными клетками костного мозга в норме и у больных лимфомами в процессе химиотерапии./В. В. Денисова, А. Д. Кулагин, И. А. Лисуков и др.// Гем и транс.- 2004 .-№ 6.-С. 16−21.
- Пунанов Ю. А. Факторы прогноза у детей со злокачественными лимфомами./ Ю. А. Пунанов // Российский онкологический журнал. -2005.-№ 2.-С. 79−80.
- Райхлин Н.Т. Регуляция и проявления апоптоза в физиологических условиях и в опухолях/Н.Т.Райхлин, А.Н.Райхлин// Руководство по иммуногистохимической диагностике опухолей человека./ под ред. С. И. Петрова и Н. Т. Райхлина.-Казань:Титул, 2004.-С.350−366.
- Райхлин Н.Т. Апоптоз и его роль в механизмах регуляции роста опухолевых клеток с множественной лекарственной устойчивость./ Н. Т. Райхлин, Е. А. Смирнова, А. Г. Перевощиков // Арх. патол.-1996.-№ 2, — С.3−8.
- Райхлин Н.Т. Скорость роста опухолевых клеток, лекарственная устойчивость и апоптоз. / Н. Т. Райхлин // Актуальные вопросы патологической анатомиии.-Челябинск.-1996.-С.32−33.
- Ройт А. Иммунология: пер с англ. /А.Ройт, Дж. Бростофф, Д.Мейл.-М. :Мир, 2000.-592с.
- Сравнение форм хронического лимфолейкоза в зависимости от мутационного статуса генов вариабельного региона иммуноглобулинов./ Е. А. Никитин, А. В. Пивник, А. Б. Судариков и др.// Тер.архив.- 2000.-№ 7.-С.52−57.
- Салтыкова Л.Б. Иммунологические маркеры в гистологической диагностике лимфом./Салтыкова Л.Б., Криволапов Ю.А.//Тер.арх.-2002.-№ 7.-С.80−87.
- Сингер М. Гены и геномы: пер. с англ., в 2 т /М.Сингер, П. Берг// М.:Мир.-1998.-Т.2.-390с.
- Скворцова Н.В. Цитокиновый профиль больных лимфомами в динамикеполихимиотерапии:автореф.дис. .канд.мед.наук: 14.00.29/Н.В.Скворцова- Новосиб.гос.мед.акад.-Новосибирск, 2005 .-30с.
- Стимуляция дифференцировки клеток рака толстой кишки LJM 1215 при экспрессии экзогенного антионкогена р53 и активированного онкогена ras./Н.Т.Райхлин, Ю. А. Володина, Е. А. Смирнова и др.// Арх. патол.-1995.-№ 5.-С.34−38.
- Структура и функция эритроцитов при лимфомах. / М. И. Лосева, Л. А. Шпагина, И. А. Лисуков и др. // Гематол. и трансфузиол.-1992.-№ 5−6.-С. 16−20.
- Хансон К.П. Эпидемиология и биология неходжкиских лимфом./ К. П. Хансон, Е. Н. Имянитов.//Практ.онкология.-№ 3.-т.5.-С. 163−168.
- Характеристика нарушений функциональной активности Т-клеток у больных лимфомами при проведении программной полихимиотерапии./ Е. Я. Шевела, С. А. Сизикова, М. А. Тихонова и др.//Гем. и транс.-2004. -№ 1.-С.80−82.
- Характеристика моноклональных антител UT1 и UT2 к белку Fas и исследование экспрессии белков Fas, FasL и Fas-зависимого апоптоза в опухолевых клетках человека различных линий./ И. Г. Кондрашева,
- A.В.Филатов, Е. Ю. Москалева и др.// Иммунол.- 2004.-№ 2.-С. 68−72.
- Хесин Р.Б. Непостоянство генома./Р.Б.Хесин// М.:Наука.-1985.-472с.
- Хронический В-клеточный лимфолейкоз у лиц моложе 30 лет: агрессивное клиническое течение и рефрактерность к химиотерапии./Е.
- B.Чигринова, Т. Е. Бялик, Л. Ю. Андреева и др.//Гем и транс.- 2004 .-№ 3.1. C.11−16.
- Циклофосфамид-индуцированный апоптоз клеток мышинной лимфосаркомы в условиях in vitro./В.И.Каледин, В. П. Николин, Т. А. Агеева и др.// Вопросы онкологии.-2000.- том 46.-№ 5.-С.588−592.
- Цитогенетика лимфомы из клеток мантийной зоны./Т. Н. Обухова, Ю. Ю. Лорие, Л. А. Водинская и др.// Тер.архив.- 2004.-№ 7.-С.70−77.
- Цитоморфологический дифференциальный диагноз и оценка p53mut, bcl-2, CD95 в периферических В-мелкоклеточных лимфомах /А.М.Ковригина, Н. А. Пробатова, И. В. Поддубная и др.//Архю патол.-2000.-№ 62.-том 5.-С.30−34.
- Шкловский Е.В. Негативные регуляторы гемопоэза./Е.В.Шкловский, И. А. Орловская, В.А.Козлов//Гематол. и трансфузиол.-1998.- т.43.- № 6.- С.36−40.
- Штерн Р.Д. Лимфома Леннерта и ангиоиммунобластная лимфаденопатия. /Р.Д. Штерн// Арх. патол.-1981.-том 103.-№ 3.-C.3-l 1.
- Экспрессия белков-регуляторов апоптоза на клетках различных вариантов неходжкиских злокачественных лимфом./ И. Б. Ковынев, Т. А. Агеева, М. И. Лосева и др.// Журнал клинической и экспериментальной медицины.-2004.- № 1−2.-С.52−60
- Экспрессия лимфоидных дифференцировочных антигенов на мембране мононуклеарных клеток периферической крови при опухолевой прогрессии лимфосаркомы./И.А.Лисуков, И. Б. Ковынев, М. И. Лосева и др.// Тер. арх.-1991 ,-№ 63(7).-С.78−80.
- Эллиниди В.Н. Практическая иммуногистохимия./ В. Н. Эллиниди, Н. В. Аникеева, Н.А.Максимова// С-Пб.:ВЦЭРМ МЧС России.-2002.-36с.
- A clinical evalution of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The non-Hodgkin's lymphoma Classification Project./Blood.-1997.-Vol.89.-P.3909−3918.
- A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (I-2)(q25-p23) translocation./Lamant L, N. Dastugue, K. Pulford et al.//Blood.-1999.-Vol.93.-P.3088−3095.
- A revised European American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group./N.Harris, E. Jaffe, H. Stein et al.// Blood.-1994.-Vol.84.-P. 13 61 -13 92.
- A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases./S.Camilleri-Broet, E. Criniere, P. Broet et al.//Blood.- 2006, Jan 1.-Vol. 107(1).-P. 190−196.
- Abd E.l. De novo nodal diffuse large B-cell lymphoma: identification of biologic prognostic factors./ E.l.Abd, A. Hameed //J E Natl Cane Inst.- 2005, Mar.-Vol.l7(l).-P.20−28.
- Adhesion molecules in the prognosis of diffuse large cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD 1 la/18), and ICAM-1 (CD54)./E.Horst, C.J.L.M.Meijer, T. Radaszkiewicz et al.// Leukemia.-I990.-Vol.4.-P.595−599.
- Allelic 7q31−32 loss is a frequent finding in splenic marginal zone lymphoma./M.Mateo, M. Mollejo, R. Villuendas R. et al.//Am J Pathol.- 1999.-Vol.154.-P. 1583−1589.
- An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis./Y.Kim, N. Suh, M. Sporn et al.//J Biol Chem.-2002.-Vol.277.-P.2320−2329.
- Analysis of p53 and Bak gene mutations in lymphoproliferative disorders developing in rheumatoid arthritis./J.X. Xu, Y. Hoshida, T. Hongyo et al.// J Cancer Res Clin 0ncol.-2006, Sep 20.-Vol.45.-P.345−358.
- Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity ./M.Shiota, S. Nakamura, R. Ichinohasama et al.//Blood.-1995.-Vol.86.-P.1954−1960.
- Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5./F.C.Kischkel, D.A.Lawrence, A. Chuntharapai et al.// Immunity.- 2000.-Vol.12.-P.611−620.
- Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: correlation with clinicaloutcome./I.S.Lossos, Y. Natkunam, R. Levy et al.//Leuk Lymphoma.- 2002, Dec.-Vol.43(12).-P.2309−2317.
- Apoptosis in murine tumors treated with chemotherapy agents./R.E.Meyn, L.C.Stephens, N.R.Hunter et al.// Anticancer Drugs.-1995.-Vol.6.-P.443.
- Apoptosis-related genes and proteins in Hodgkin’s disease./A.F.Lauritzen, P.H.Moller, T. Nedergaard et al.//APMIS.-1999, Jul.-Vol.l07(7).-P.636−644.
- Apoptotic protease activating factor (Apaf-l)-independent cell death suppression by Bcl-2/ M. Haraguchi, S. Torii, S. Matsuzawa et al.// J Exp Med.-2000.-Vol.l91.-P.1709−1720.
- Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphomas./A.Lopez-Guillermo, E. Montserrat, F. Bosch et al.//J Clin Oncol.- 1994.-Vol.12.-P. 1343−1348.
- Armitage J. New approach to classifying Non-Hodgkin's lymphomas: clinical features of the major histologic subtypes./J.Armitage, D.J.Weisenburger//Clin Oncol.- 1998.-Vol.l6.-P.2780−2795.
- Armitage J.O. Diffuse histiocytic lymphoma after histologic conversion: a poor prognostic variant./J.O.Armitage, F.R.Dick, M.P.Corder//Cancer Treat Rep.-1981.-Vol.65.-P.413−418.
- Ashkenazi A. Apoptosis control by death and decoy receptors./A.Ashkenazi, V.M.Dixit// Curr Opin Cell Biol.- 1999.-Vol.l 1.-P.255−260.
- Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma-a Nordic Lymphoma Group study./M.Jerkeman, H. Anderson, M. Dictor et al.//Ann Hematol.- 2004, Jul.-Vol.83(7).-P.414−419.
- Au W.Y. Molecular epidemiology of follicular lymphoma in Chinese: relationship with bcl-2/IgH translocation and bcl-6 397G/C polymorphism./W.Y.Au, A. Fung, R. Liang//Ann Haematol.- 2005, Aug.-Vol.84(8).-P.506−509.
- Autoantibodyassociated cross-reactive idiotype-bearing human B lymphocytes: distribution and characterization, including Ig VH gene and CD5 antigen expression./G.Inghirami, D.R.Foitl, A. Sabichi A et al.//Blood.-1991.-Vol.78.-P.1503−1515.
- Bagot M. Epidermotropic T cell lymphomas as models for tumor progression/M.Bagot, A. Bensussan//Med Sei (Paris).- 2006, Feb.-Vol.22(2).-P.192−196.
- Bastion Y. Is the International Prognostic Index for aggressive lymphoma patients useful for follicular lymphoma patients?/Y.Bastion, B. Coiffier B.// J Clin Oncol.- 1994.-Vol. 12.-P. 1340−1342.
- Bax suppresses tumorigenesis and stimulates apoptosis in vivo./ C. Yin, C.M.Knudson, S.J.Korsmeyer et al.//Nature.- 1997.-Vol.385.-P.637−640.
- BCL-2, P53, S-Phase Fraction, CD95 & Drug Resistance in NHL/E.l.Magdy, M.D.Bordini, E.l.Ashraf et al. // Blood News Bulletin.-2000.-Vol.3.- P.21−30.
- Bcl-2 delay of alkylating agent-induced apoptotic death in a murine hemopoietic stem cell line./L.J.Fairgairn, G.J.Cowling, T.M.Dexter et al.// Mol Carcinogen.-1994,-Vol. 11.-P.49.
- Bcl-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy./J.C.Reed, T. Miyashita, S. Takayama et al.// J Cell Biochem.- 1996.-Vol.60.-P.23−32.
- Bcl-2 gene enables rescue from in vitro myelosuppression (bone marrow cell death) induced by chemotherapy./S.Kondo, D. Yin, J. Takeuchi et al. //Br J Cancer.-1994.-Vol.70.-P.421
- Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair./S. Kamesaki, H. Kamesaki, T.J. Jorgensen et al.// Cancer Res.-1993.-Vol. 53.-P.4251.
- Bcl-2-immunoglobulin transgenic mice demonstrated extended B cell survival and follicular lymphoproliferation./T.J.McDonnell, N. Deane, F.M.Platt et al.// Cell.- 1989.-Vol.57.-P.79−88.
- BCL-6 protein is expressed in germinal-center B cell./ G. Cattoretti, C.C.Chang, K. Cechova et al.//Blood.-1995.-Vol.86.-P.45−53.
- BCL-6 expression in reactive lymphoid tissue and in B-cell non-Hodgkin's lymhpomas./S.Pittaluga, N.A.Ayoubi, I. Wlodarska et al.//J Pathol.-1996.-Vol.179.-P. 145−150.
- Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities./B.F.Skinnider, D.E.Horsman, B. Dupuis et al.// Hum Pathol.- 1999.-Vol.30.-P.803−808.
- BCL-6 mutations in normal germinal center B cell: evidence of somatic hupermutation acting outside Ig loci./L.Pasqualucci, A. Migliazza, N. Fracchiolaa et al.//Proc Natl Acad Sci U S A.-1998.-Vol.95 .-P. 11 816−11 821.
- BER-H2. a new anti-Ki-1 (CD30) monoclonal antibody directed at a formal-resistant epitope./R.Schwarting, J. Gerdes, H. Durkop et al.// Blood.- 1989.-Vol.74.-P. 1678−1689.
- Berman E. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells./E.Berman, M. McBride//Blood.-1992.-Vol.79.-P.3267−3273.
- Bid, bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane./T.Kuwana, M.R.Mackey, G. Perkins et al.// Cell.-2002.-Vol.lll.-P.331−342.
- Bowen J. Mitosis and apoptosis. Matters of life and death. /J.Bowen, S. Bowen, A.L.Jnes.-London:Chapman &Hall.-1998.-p.l82.
- Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma. An 18-year experience from the British Columbia Cancer Agency./T.N.Shenkier, N. Voss, R. Fairey et al.// J Clin Oncol.- 2002.-Vol.20.-P. 197−204.
- Burke J.S. The Histopathologic Classification ofNon-Hodgkin 's Lymphomas: Ambiguities in the Working Formulation and Newly Reported Categories./J.S.Burke //Sem.0ncol.-I990.-Vol.l7.-№ 1-P.3-I0.
- Butcher E.C. Cellular and mechanisms that direct leukocyte traffic./E.C.Butcher//Am J Pathol.-1990.-Vol. 136.-P.3−11.
- Buxbaum J. Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and heavy chain deposition disease./J. Buxbaum.//Haematol.Oncol.Clin.North.Am.-1992.-Vol.6.-P.323−346.
- Cancer Statistics, 2006/A.Jemal, R. Siegal, E. Ward et all. //Cancer Journal for Clinicians.-2006-May 28- Vol. 56.- P.106−130.
- Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma./D.Catovsky, E. Matutes// Semin Hematol.- 1999.-Vol.36.-P.148−154.
- CD30(+)anaplastic large cell lymphoma: a review of its histopathologic genetic, and clinical features./H.Stein, H.D.Foss, H. Dukop et al.//Blood.-2000.-Vol.96.-P.3681−3695.
- CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor./R.Stauder, W. Eisterer, J. Thaler et al.// Blood.- 1995.-Vol.85.-P.2885−2999.
- Cellular adaptation and cancerogenesis./ F. La Torre, A. Silpigni, R. Tomasello et al. //Minerva Med.- 1998, Jun.-Vol.89(6).-P.229−239.
- Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited./P.Jr.Bunn, P. Schein, P. Banks, V.Jr. DeVita//Blood.- 1976.-Vol.47.-P.5−3.
- Chan J.K.C. Tumors of the lymphoreticular system, including spleen and thymus/J.K.C.Chan //Diagnostic histopathology of tumors./ed.Fletcher C.M.D.-New-York:Churchill Livingstone, 2000.-P.1099−1317.
- Characteristics of cancer cell death after exposure to cytotoxic drugs in v/iro./L.I.Huschtscha, W.A.Bartier, C.E.A.Ross et al.// Br J Cancer.- 1996.-Vol.73.-P.54.
- Charames G.S. Genomic instability and cancer. /G.S.Charames, B. Bapat//Curr Mol Med.- 2003, Nov.-Vol.3(7).-P.589−596.
- Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma./T.Miller, S. Dahlberg, J. Cassady et al.// Engl J Med.- 1998.-Vol.339.-P.21−26.
- Chemotherapy for diffuse large-cell lymphoma. Rapidly responding patients have more durable remission./J.Armitage, D. Weisenburger, M. Hutchins et al.//J Clin Oncol.- 1986.-Vol.4.-P.160.
- Chemotherapy-induced apoptosis in epithelial ovarian cancers. /L.J. Havrilesky, A. Elbendaiy, J.A.Hurteau et al.// Obstet Gynecol.-1995.-Vol. 85.-P.1007.
- Chen L. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia / L. Chen, J. Apgar, L. Huynh //Blood.-2005.-Mar l-Vol.l05.-№ 5.-P.2036−2041.
- Chow M. Clonal selection versus genetic instability as the driving force in neoplastic transformation./M.Chow, H. Rubin//Cancer Res.- 2000, Nov 15.-Vol.60(22).-P.6510−6518.
- Chromosomal breakpoints and structursl alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma./P.G.Pelicci, D.M.Knowles, I. Magrath et al.//Proc Natl Acad USA.-1986.-Vol.83.-P.2984−2988.
- Chromosomal and gene amplification in diffuse large B-cell lymphoma./P.Rao, J. Houldsworth, K. Dyomina et al.//Blood.-1998.-Vol.92.-P.234−240.
- Chromosome 11 translocation brekpoins at the PRADl/cyclin D1 gene locus in centrocytic lymphoma./ M.E.Williams, S.H.Swerdlow, C.L.Rosenberg et al.// Leukemia.-1993 .-Vol.7.-P.241 -245.
- Chromosome translocation involving band 7q35 or 7pl5 in childhood T-cell leukemia/lymphoma./Y.Kaneko, N. Maseki, C. Homma et al.// Blood.- 1988.-Vol.72.-P.534.
- Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study./A.D.Krol, J.C.Kluin-Nelemans, H.L.Haak et al.//J Clin Oncol.- 1996, Jul.-Vol.l4(7).-P.2131−2138.
- Clinical relevance of immunologic phenotype in diffuse large cell lymphoma./S.J.Horning, R.S.Doggert, R.A.Warnke et al.// Blood.- 1984.-Vol.63.-P.1209−1215.
- Clinical features and prognosis of follicular large-cell lymphoma. A report from the Nebraska lymphoma study group./J.Anderson, J. Vose, P. Bierman et al.// J Clin Oncol.- 1993,-Vol.l 1.-P.218−224.
- Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation. A pediatric oncology group study ./W.M.Crist, J.J.Shuster, J. Falletta et al.// Blood.- 1988.-Vol.72.-P.1891−1897.
- Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma./L.Colomo, A. Lopez-Guillermo, M. Perales et al.//Blood.-2003,Jan 1.-Vol.101 (l).-P.78−84.
- Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins./E.Sanchez, I. Chacon, M.M.Plaza et al.//J Clin Oncol.- 1998, May.-Vol.l6(5).-P.1931−1939.
- Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma./M.Kramer, J. Hermans, E. Wijburg et al.// Blood.- 1998,-Vol.92.-P.3152−3162.
- Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma. An analysis of 83 cases./ S. Tang, L. Visser, B. Hepperle et al.// J Clin Oncol.-1994.-Vol.12.-P. 149−154.
- Cloning the chromosomal breakpoint of t (14−18) human lymphomas. Clustering around on chromosome 14 and near a transcriptional unit on 18./A.Bakhski, J. Jensen, P. Goldman et al.// Cell.- 1985.-Vol.41.-P.899.
- Clusters of chromosome 9 aberrations are associated with clinico-pathologic subsets of non-Hodgkin's lymphoma./K.Offit, N. Parsa, S. Jhanwar et al.// Genes Chromosom Cancer.- 1993.-Vol.7.-P.l-7.
- Coiffer B. Prognosis of aggressive lymphomas: a study of five prognostic models with patients included in the LNH-84 regimen./B.Coiffer, E. Lepage // Blood.-1989, Aug.-Vol.74(2).-P.558−564.
- Coleman M. COP-BLAM treatment of large cell lymphoma: a status report. /M.Coleman, D. Boyd, M.E.A.Beshevkin //In: Skarin AT, editor. Update on treatment for diffuse large cell lymphoma.- New York: Park Row, 1986.- p. 63.
- Coleman W.B. Molecular mechanisms of human carcinogenesis. /W.B.Coleman, G.J.Tsongalis//EXS.-2006.-Vol.96.-P.321 -349.
- Combination chemotherapy of advanced non-Hodgkin's lymphoma with bleomycin, Adriamycin, cyclophosphamide, vincristine and prednisone (BACOP)./A.Skarin, D. Rosenthal, W. Maloney et al.//Blood.- 1977.-Vol.49.-P.759.
- Comparative analysis of apoptosis and inflammation genes of mice and humans/J.C.Reed, K. Doctor, A. Rojas et al.// Genome Res.- 2003.-Vol.l.-P.1376−1388.
- Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions/C.M.Eischen, T.J.Kottke, L.M.Martins et al.//Blood.- 1997, Aug 1.-Vol.90(3).-P.935−943.
- Comparison of cytogenetic analysis, southern analysis, and polymerase chain reaction for the detection of t (14- 18) in follicular lymphoma./
- D.E.Horsman, R.D.Gascoyne, R.W.Couplend et al.//Am J Clin Phatol.-1995.-Vol. 103 .-P.472−478.
- Comparison of MALT and non-MALT primary large cell lymphoma of the stomach. Does histologic evidence of MALT affect chemotherapy response?/C.Hsu, C.L.Chen, L.T. Chen et al.// Cancer.- 2001.-Vol.91.-P.49−56.
- Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma./R.Fisher,
- E.Gaynor, S. Dahlberg et al.// N Engl J Med.- 1993.-Vol.328.-P.1002.
- Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma./L.Gordon, D. Harrington, J. Andersen et al.// New Engl J Med.- 1992.-Vol.327.-P. 1342−1349.
- Comparison of Apoptosis in Wild-Type and Fas-Resistant Cells: Chemotherapy-Induced Apoptosis Is Not Dependent on Fas/Fas Ligand Interactions./Blood.-1997,Aug.-Vol. 90.- № 3.-P. 935−943.
- Concurrent translocation of BCL2 and MYC with a single immunoglobulin locus in high-grade B-cell lymphomas./S.Knezevich, O. Ludkovski, C. Salski et al.//Leukemia.- 2005, Apr.-Vol.l9(4).-P.659−663.
- Consistent presence of isochromosome 7q in hepatosplenic T gamma/delta lymphoma: a new cytogenetic-clinicopathologic entity./C.Wang, H. Tien, M. Lin etal.// Genes Chromosomes Cancer.- 1995.-Vol.l2.-P.161−164.
- Constitutive expression of the c-H-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdomyosarcoma cell line./K.Nooter, A.W.M.Boersma, R.G.Oostrum et al.// Br J Cancer.-1995.-Vol.71.-P.556.
- Copelan E. The biology and treatment of acute lymphoblastic leukemia in adults./E.Copelan, E. McGuire// Blood.- 1995.-Vol.85.-P.l 151−1168.
- Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma./A.Lopez-Guillermo, F. Cabanillas, T.I.McDonnell et al.//Blood.-1999, May 1.-Vol.93(9).-P.3081−3087.
- Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer ./A.E.Pinto, S. Andre, C. Laranjeira et al.//Pathology.- 2005, Feb.-Vol.37(l).-P.45−50.
- Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL)./J.P.Marie, J.N.Bastie, F. Coloma et al.// Leukemia.- 1993.-Vol.7.-P.821−824.
- Cytochrome c and dATP-dependent formation of Apaf-l/Caspase-9 complex initiates an apoptotic protease cascade ./P.Li, D. Nijhawan, I. Budihardjo et al.// Cell.- 1997.-Vol.91 .-P.479−489.
- Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations./K.Offit, G. Wong, D. Filippa et al.// Blood.- 1991 .-Vol.77.-P. 1508−1515.
- Cytogenetic analysis of 363 consecutively ascertained diffuse large B-cell lymphomas./J.Cigudosa, N. Parsa, D. Louie et al.//Genes Chromosomes Cancer.- 1999.-Vol.25.-P. 123−133.
- Dabbs D.J. Diagnostic immunohistochemistry.-New-York:Churchill Livingstone, 2002.-673p.
- Dallman C. Purification of primary malignant B-cells and immunoblot analysis of bcl-2 family proteins./C.Dallman, G. Packham //Methods Mol Med.-2005.-Vol.115.-P.l-13.
- Dalton W.S. Alternative (non-P-glycoprotein) mechanisms of drug resistance in non-Hodgkin's lymphoma./Hematol Oncol North Am.- 1997, Oct.-Vol.l l (5).-P.975−986.
- D’Amico A.V. Apoptosis and a re-investigation of the biologic basis for cancer therapy./A.V.D'Amico, W.G.McKenna // Radiother Oncol.-1994.-Vol.33.-P.3.
- Dang C.V. The great MYC escape in tumorigenesis./ C.V.Dang, K.A.O'donnell, T. Juopperi//Cancer Cell.- 2005, Sep.-Vol.8(3).-P. 177−178.
- De Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors./D.de Jong//J Clin Oncol.- 2005, Sep 10.-Vol.23(26).-P.6358−6363.
- De Wolf-Peeters C, Pittaluga S. Mantle-cell lymphoma./C.De Wolf-Peeters, S. Pittaluga//Ann Oncol.- 1994.-Vol.5(Suppl l).-P.35−37.
- Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications./B.J.Kuss, R.G.Deeley, S.P.C.Cole et al.//The Lancet.- 1994.- Vol.343 .-P. 1531−1534.
- Delvers P.J. The immune system. Second of two parts./ P.J.Delvers, I.M.Roitt //N Engl J Med.-2000.-Vol.343.-P. 108−117.
- De Ment S.H. Assotiation between mediastinal germ cell tumors and hematologic malignancies: an update./S.H.deMent//Hum Patol.-1990.-Vol.699−703.
- Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK l./K.Pul ford, L. Lamant, S.W.Morris et al.// Blood.-1997.-Vol.89.-P. 1394−1404.
- Detection of P-glycoprotein activity on normal and leukemic CD34+ cells./B.Drenou, O. Fardel, L. Amiot et al.// Leukemia Research.- 1993.-Vol. 17.-P.1031—1035.
- Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123./C.Ludescher, J. Thaler, D. Drach et al.// British Journal of Haematology.- 1992.-Vol.82.-P. 161−168.
- Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct phatogenetic forms of Burkitt lymphoma./A.Neri, F. Barriga, D.M.Knovles et al.//Proc Natl Acad USA.-1988.-Vol.85.-P.2748−2752.
- Differential requirement for caspase 9 in apoptotic pathways in vivo/ R. Hakem, A. Hakem, G.S.Duncan et al. //- Cell.- 1998.-Vol.94.-P.339−352.
- Differential expresison of CD54/intercellular adhesion molecule-1 in myeloid leukemias and in lymphoprolioferative disorders./M.Maio, A. Pinto, A. Carbone et al.//Blood.- I990.-Vol.76.-P.783−790.
- Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy ./R.Fisher, V. DeVita, S. Hubbard et al.// Ann Intern Med.- 1983.-Vol.98.-P.304.
- Diffuse large B-cell lymphoma of bone: an analysis of differentiation-associated antigens with clinical correlation./L.de Leval, K.M.Braaten, M. Ancukiewicz et al.//Am J Surg Pathol.- 2003, Sep.-Vol.27(9).-P.1269−1277.
- Discordance between surface and cytoplasmic expression of the leu-4 (T3) antigen in thymocytes and in blast cells from childhood T lymphoblastic malignancies./M.P.Link, S.J.Stewart, R.A.Warnke et al.//J Clin Invest.- 1985.-Vol.76.-P.248−253.
- Discrepant expression of membrane and soluble isoforms of Fas (CD95/APO-1) in adult T-cell leukaemia: soluble Fas isoform is an independent risk factor for prognosis./S.Kamihira, Y. Yamada, M. Tomonaga et al.// Br J Haematol.-1999.-Vol.107.-P.851−860.
- Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline./ Fan S, M.L.Smith, DJ. Rivet II er al.// Cancer Res.-1995.-Vol.55.-P.1649.
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling./ A. Alizadeh, M. Eisen, R. Davis et al.// Nature.- 2000.-Vol.403.-P.503−511.
- Dive C. Induction of apoptosis-new targets for cancer chemotherapy. /C.Dive, C.A.Evans, A.D.Whetton// Cancer Biol.-1992 -Vol. 3.-P.417.
- Down-regulation of c-FLIP sensitizes DU145 prostate cancer cells to fas-mediated apoptosis./M.L.Hyer, S. Sudarshan, Y. Kim et al.// Cancer Biol Ther.-2002.-Vol. 1 .-P.405−406.
- Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients./P.Zinzani, S. Storti, A. Zaccaria et al.// Blood.- 1999.-Vol.94.-P.33−38.
- Elevated circulating levels of TNF-alpha and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients./G.Salles, J. Bienvenu, Y. Bastion et al.//Br J Haematol.- 1996.-Vol.93.-P.352−359.
- Enhanced sensitivity with a novel TCRgamma PCR assay for clonality studies in 569 formalin-fixed, peraffin-embadded (FFPE) cases. /A.E.Krafft, J.K.Taubenberger, Z.M.Sheng et al.//Mol Diagn.-1999.-Vol.4.-P.l 19−133.
- Enhancement of CDDP cytotoxicity by caffeine is characterized by apoptotic cell death./N.Shinomiya, M. Shinomiya, H. Wakiyama et al.//Exp Cell Res.-1994.-Vol.210.-P.236.
- EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma./W.Wilson, G. Bryant, S. Bates et al.// J Clin Oncol.-1993.-Vol.ll.-P.1573−1582.
- Epstein J, Xiao HQ, Oba BK. P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD./J.Epstein, H.Q.Xiao, B.K.Oba// Blood.- 1989.-Vol.74.-P.913−907.
- Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma./R.Meyer, I. Quirt, J. Skillings et al.// N Engl J Med.- 1993.-Vol.329.-P.1770−1776.
- Evaluation of multidrug resistant phenotype by flow cytometry with monoclonal antibodies and functional tests./G.Lizard, M. Maynadie, P. Roignotet al.//Bull Cancer.- 1995, Mar.-Vol.82(3).-P.211−217.
- Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis./M.Berglund, U. Thunberg, R.M.Amini et al.//Mod Phatol.-2005, Aug.-Vol. 18(8).-P. 1113−1120.
- Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma./A.Melnyk, A. Rodriguez, W. Pugh et al.// Blood.- 1997.-Vol.89.-P.4514−4520.
- Evenitoba-Johnson K.E. Lymphoproliferative disorders assotiated with congenital immunodeficiencies./ K.E.Evenitoba-Johnson, E.S.Jaffe // Semin. Diagn. Pathol.-1997.-Vol.l4.-P.35−47.
- Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants./M.T.Hemann, A. Bric, J. Teruya-Feldstein et al.//Nature.- 2005, Aug 11 .-Vol.436(7052).-P.807−811.
- Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma/I.S.Lossos, C.D.Jones, R. Warnke et al. //Blood.- 2001- Aug 15.-Vol.98(4)/-P.945−951.
- Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas./N.Akyurek, Y. Ren, G.Z.Rassidakis et al.// Cancer/- 2006, Sep 18.-Vol.l07(8).-P. 1844−1851.
- Expression of a multidrug-resistance gene in human tumors and tissues. / A.T.Fojo, K. Ueda, D.J.Slamon et al.// Proceedings National Academy of
- Sciences USA.- 1987. Vol.84. — P.265−269.
- Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. /K.C.Anderson, M.P.Bates,
- B.L.Slaughenhoupt et al.//Blood.-1984.-Vol.63.-P. 1424−33.
- Expression of the multidrug resistance-associated protein (mrp) in acute leukaemia./S.M.Hart, K. Ganeshaguru, A.V.Hoffbrand et al.// Leukemia.- 1999,-Vol.48.-P.2163−2168.
- Expression of a single gene, BCL-2, strongly predicts survival in patients with diffuse large B-cell lymphoma./LS.Lossos, R. Warnke et al.//Blood.-1999, Sep 18.-Vol.77(3).-P.815−820.
- Expression of LFA-1 in non-Hodgkin's lymphoma. /L.J.Medeiros, L.M.Weiss, L.J.Picker et al.// Cancer.- 1989.-Vol.63.-P.255−259.
- Expression of lymphocyte homing receptor antigen in non-Hodgkin's lymphoma./L.J.Picker, L.J. Medeiros, L.M.Weiss et al.// Am J Pathol.- 1988.-Vol. 13 0.-P.496−5 04.
- Expression of p53, p21, mdm2, Rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue./K.Stefanaki, M. Tzardi,
- C.Kouvidou et al.//Anticancer Res.- 1998, Jul-Aug.-Vol.l8(4A).-P.2403−2408.
- Expression of mp53 and c-Myc in diffuse large B-cell lymphoma./ C. Schultz, B. Kampalath, et al.//Blood.- 2000.-Vol.87(3).-P.325−336.
- Expression of P53 and bcl-2 proteins in T-cell lymphoblastic lymphoma: prognostic implications./K.N.Naresh, S.D.Banavali, G. Bhatia et al.//Leuk Lymphoma.-2002, Feb.-Vol.43(2).-P.333−337.
- Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively./L.Tracey, A. Perez-Rosado, M.J.Artiga et al.//J Phatol.- 2005, Jun.-Vol.206(2).-P.123−134.
- Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia./L.Chen, J. Apgar, L. Huynh et al.//Blood.- 2005, Mar 1.-Vol.l05(5).-P.2036−2041.
- Expression pattern of N-cell-associated chemokine receptops and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma./D.Jones, C.'Hara, M.D.Kraus et al.//Blood.-2000.-Vol.96.-P.685−690.
- Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study ./J.Lee, C. Suh, Y.H.Park et al.//J Clin Oncol.-2006, Feb.-Vol 24.-№ 4.-P.612−618.
- Extranodal peripheral T-cell and NK-cell neoplasms./ E.S.Jaffe, L. Krenacs, D.W.Kingma et al.//Am J Clin Paphol.-1999.-Vol.111.-P.46−55.
- Fas/FasL signaling allows extracelluar-signal regulated kinase to regulate cytochrome c release in oridonin-induced apoptotic U937 cells./Y.Q.Liu, Z.Q.Mu, S. You et al.// Biol Pharm Bull.- 2006, Sep.-Vol.29(9).-P. 1873−1879.
- Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome./Y.Kojima, H. Tsurumi, N. Goto et al.//Eur J Haematol.- 2006, Jun.-Vol.76(6).-P.465−472.
- Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer./J.OConnell, M. Bennett, G. O'sullivan et al.// J Pathol.-1998.-Vol.186.-P.240−246.
- Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort 1./J.Zhang, C. Cado, A. Chen et al.//Nature.-1998.-Vol.392.-P.296−299.
- Fialcow P.J. Clonal evolutions of human myuloid leukemias./P.J. Fialcow//Genes and cancer.-N-York:Alan R.Liss.-1984.-260p.
- Fludarabine phosphate for the treatment of low grade lymphoid malignancy./J.Whelan, C. Davis, S. Rule et al.// Br J Cancer.- 1991.-Vol.64.-P.120−123.
- Fluorescent cellular indicators are extruded by the multidrug resistance protein./ L. Homolya, Z. Hollo, U.A.Germann et al.// J Biol Chem.- 1993.-Vol.268.-P.21 493−2146.
- Follicular lymphoma international prognostic index./P.Solal-Celigny, P. Roy, P. Colombat et al.//Blood.- 2004, Sep 1.-Vol. 104(5).-P. 1258−1265.
- Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features./ J. Rodriguez, P. McLaughlin, F. Hagemeister etal. //Blood.- 1999.-Vol.93.P.2202−2207.
- Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973−1981./J.Rodriguez, P. McLaughlin, L. Fayad et al.//Ann Oncol.-2000,Dec.-Vol.ll (12).-P.1551−1556.
- Follicular lymphoma. Prognostic factors for response and survival. /C.J.Gallagher, W.M.Gregory, A.E.Jones et al.// J Clin Oncol.-1986.-Vol.4.-P.1470−1480.
- Foulds L. Mammary tumours in hybrid mice- growth and progression of spontaneous tumours/ L. Foulds // Br J Cancer.-1949-Sep 3.-Vol.3.-P.345−375.
- Foulds L. Tumor progression/L.Foulds//Cancer Res.- 1957- Jun 17.-Vol.5.- P.355−356.
- Freedman A.S. Biology and Management of Histologic Transformation of Indolent Lymphoma./A.S. Freedman//2005 by the American Society of Hematology.-Print ISSN: 1520−4391- Online ISSN 1520−4383.
- French D.L. The role of somatic hypermutation in the generation of antibody diversity ./D.L.French, R. Laskov, M.D.Scharff//Science.-1989.-Vol.244.-P.1152−1157.
- Frequency of central nervous system involvement in primary cutaneous B-cell lymphoma./M.W.Bekkenk, T.J.Postma, C.J.Meijer et al.// Cancer.- 2000.-Vol.89.-P.913−919.
- From Gene Expression Analysis to Tissue Microarrays./S.Ek, U. Andreasson, S. Hober et al.//Mol Cel Prot.-2006.-Vol.5.-P.1072−1081.
- Functional validation of genes implicated in lymphomagenesis: an in vivo selection assay using a Myc-induced B-cell tumor./D.Yu, D. Cozma, A. Park et al.//Ann N Y Acad Sci.- 2005, Nov.-Vol.l059.-P.145−159.
- Gamma delta T-cell lymphoma of the skin: a clinical, microscopic and molecular study./J.R.Toro, M. Beaty, L. Sorbara et al.//Arch Dermatol.-2000.-Voll36.-P. 1024−1032.
- Gattiker H.H. Spontaneous regression in non-Hodgkin's lymphoma./H.H.Gattiker, E. Wiltshaw, D.A.Galton// Cancer.- 1980.-Vol.45.-P.2627−2632.
- Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas./B.Ballester, O. Ramuz, C. Gisselbrecht et al.//0ncogene.-2006, Mar 9.-Vol.25(10).-P. 1560−1570.
- Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand./T.Takahashi, M. Tanaka, C.I.Brannan et al.// Cell.-1994.-Vol.76.-P.969−976.
- Genetic analysis of splenic lymphoma with villous lymphocytes, a Group Francais d’Hematologie Cellulaire (GFHC) study./X.Troussard, L. Mauvieux, I. Radford-Weiss et al.//Br J Haematol.- 1998.-Vol.l01.-P.712−721.
- Genetic testing for hereditary nonpolyposis colorectal cancer./R.Hoedema, T. Monroe, C. Bos et al.//Am Surg.- 2003, May.-Vol.69(5).-P.387−391.
- Genetic ablation of protein tyrosine phosphatase IB accelerates lymphomagenesis of p53-null mice through the regulation of B-cell development./N.Dube, A. Bourdeau, K.M.Heinonen et al.//Cancer Res.-2005, Nov 1.-Vol.65(21).-P. 10 088−10 095.
- Genetic alterations in B-cell non-Hodgkin's lymphoma./Z.Magic, T. Novkovic, B. Cikota et al.//V ojnosanit Pregl.- 2005, Feb.-Vol.62(2).-P.87−96.
- Ghetie M-A. Anti-CD 19 Antibodies Inhibit the Function of the P-gp Pump in Multidrug-resistant B Lymphoma Cells./M-A.Ghetie, V. Ghetie, E.S.Vitetta// Clin Cancer Res.-1999, Dec.-Vol.5(12).-P.3920−3927.k
- Ghielmini M. Does the FLIPI apply to grade 3 follicular lymphoma?/ M. Ghielmini, 0, Mora//Blood.-2005, June.- Vol. l05.-№ 12.-P.4892−4893.
- Goss P. Non-Hodgkin's lymphomas in elderly patients./P.Goss//Leuk Lymphoma.- 1993 .-Vol. 10.-P. 147−156.
- Green D.R. Mitochondria and apoptosis / D.R.Green, J.C.Reed // Science.- 1998 .-Vol.281 .-P. 1309−1312.
- Hannun Y.A. Apoptosis and the Dilemma of Cancer Chemotherapy./ Y.A.Hannun// Blood.-1997.- Vol.89.- № 6 (15).-P. 1845−1853.
- Hayat M.A. Microscopy, immunohistohemistry, and antigen retrieval methods: for ligth and electron microscopy./M.A. Hayat -New-York: Kluwer Academic./PIenum Publishers.-2002.-355p.
- Hematopathology Approaches to Diagnosis and Prognosis of Indolent B-Cell Lymphomas./D.Randy, J. Gascoyne et al.// 2002, Hematology Online by The American Society of Hematology. Print ISSN 1520−4391- Online ISSN 1520−4383.
- Hepatosplenic T-cell lyphoma: a district clinicopathologic entity of cytotoxic gamma delta T-cell origin./C.B.Cooke, L. Krenacs, M. Stetler-Stevenson et al.//Blood.-1996.-Vol.88.-P.4265−4274.
- Hepatosplenic T-cell lymphoma: sinusoidal localization of malignant cells expressing the T-cell receptor g/d./J.Farcet, P. Gaulard, J. Marolleau et al.// Blood.- 1990.-Vol.75.-P.2213−2219.
- Heterogeneity of T cell lymphoblastic malignancies. /L.M.Nadler, E.L.Reinherz, H.J.Weinstein et al.//Blood.- I980.-Vol.55.-P.806−810.
- Higgins C.F. Is the multidrug transporter a flippase?/C.F.Higgins, M.M.Gottesman//Trends Biochem Sci.- 1992.-Vol.17.-P. 18−21.
- High expression of the multidrug resistance-associated protein (mrp) in chronic and prolympho-cytic leukaemia./H.Burger, K. Nooter, P. Sonneveld P et al.// British Journal of Haematology.- 1994.-Vol.88.-P.348−356.
- High functional P-glycoprotein activity is more often present in T-cell acute lymphoblastic leukaemic cells in adults than in children./SLPlasschaert, E. Vellenga, E.S.de Bont et al.//Leuk Lymphoma.- 2003 Jan.-Vol.44(l).-P.85−95.
- Histogenetic correlations between subcategories of small non-cleaved cell lymphomas./T.Yano, J. van Krieken, I. Magrath et al.// Blood.-1992.-Vol.79.-P.1282−1290.
- Histologic progression in non-Hodgkin's lymphoma. /S.M.Hubbard, B.A.Chabner, V.T.DeVita et al. //Blood.-1982.-Vol.59.-P.258−264.
- HLA-DR (la) immune phenotype predicts outcome for patients with diffuse large cell lymphoma./T.P.Miller, S.M.Lippman, C.M.Spier et al.// J Clin Invest.- 1988.-Vol.82.-P.370−372.
- Hollema H. T-lymphoblastic and peripheral T-cell lymphomas in the northern part of The Netherlands. An immunologic study of 29 cases./H.Hollema, S. Poppema // Cancer.- 1989.-Vol.64.-P. 1620−1628.
- Horning S.J. The natural history of initially untreated low-grade non-Hodgkin's lymphoma./S.J.Horning, S.A.Rosenberg // N Engl J Med.- 1984.-Vol.31 l.-P.1471−1508.
- Hsu H. The TNF receptor 1-associated protein TRADD signals cell death and NFkappaB activation./H.Hsu, J. Xiong, D.V.Goeddel//Cell.- 1995.-Vol.81.-P.495−504.
- Huang D.C. BH3-only proteins-essential initiators of apoptotic cell death./D.C.Huang, A. Strasser//Cell.- 2000.-Vol.l03.-P.839−842.
- Hypercalcemia and osteoclast proliferation in adult T-cell leucemia./T.Kiyokawa, K. Yamaguchi, M. Takeya et al.//Cancer.-1987.-Vol.59.-P.1187−1191.k
- Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma./I.Khouri, J. Romaguera, H. Kantarjian et al.//J Clin Oncol.- 1998.-Vol.l6.-P.3 803−3 809.
- Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD./ M.A.Shipp, D.P.Harrington, M.M.Klatt et al. //Ann Intern Med.-1986, Jun.-Vol.l04(6).-P.757−765.
- IgV Mutation of blastoid mantle cell lymphoma./S.B.Cogliatti, F. Bertoni, D.R.Zimmermann et al.//J Phatol.- 2005, Jul.-Vol.206(3).-P.320−327.
- Immunoglobulin V genes and CD38 expression in CLL./ T.J.Hamblin, J.A.Orchard, A. Gardiner et al.// Blood.- 2000.-Vol.95.-P.2455−2457.
- Immunohistochemical profiling based on Bcl-2, CD 10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma./J.J.Muris, C.J.Meijer, W. Vos et al. //J Pathol.- 2006, Apr.-Vol.208(5).-P.714−723.
- Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms./ S.Z.Kim, K.U.Chow, N. Kukoc-Zivojnov et al.//Leuk Lymphoma.-2004, Oct.-Vol.45(10).-P.2037−2045.
- Immunophenotypic criteria for the diagnosis of non-Hodgkin's lymphoma./L.J.Picker, L.M.Weiss, L.J.Medeiros et al.//Am J Pathol .-1987.-Vol.128.-P. 181−201.
- Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high-dose methotrexate alternating with standard agent (MBACOD)./A.Skarin, G. Canellos, D. Rosenthal et al.// J Clin Oncol.- 1983.-VoU.-P.91.
- Incidence of BCL-2 gene rearrangements in Argentinean non-Hodgkin lymphoma patients: increased frequency of breakpoints outside of MBR and
- MCR./M.F.Noriega, C. De Brasi, M. Narbaitz et al.//Blood Cells Mol Dis.- 2004, Jan-Feb.-Vol.32(l).-P.232−239.
- Increased serum levels of soluble Fax in progressive B-CLL./L.M.Osorio, M. Aguilar-Santelises, A. De Santiago et al.// Eur J Haematol.- 2001.-Vol.66.-P.342−346.
- Increased expression of the multidrug resistance-associated protein gene in relapsed leukemia./E.Schneider, K.H.Cowan, H. Bader et al.// Blood.- 1995.-Vol.85.-P.0186−190.
- Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by monoclonal antibody Ki-67. /T.Grogan, S. Lippman, C. Spier et al.// Blood.- 1988.-Vol.71.-P.l 157.
- Indolent nonfollicualr lymphomas: characteristics, treatment, and outcome./B.Coiffier, C. Thieblemont, P. Felman et al.// Semin Hematol.- 1999.-Vol.36.-P.198−208.
- Induction of DNA strand breaks associated with apoptosis during treatment of leukemias./W.Gorczyca, K. Bigman, A. Mittelman et al.// Leukemia.-1993.-Vol.7.-P.659.
- Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C./F.J.Keith, D.A.Bradbury, Y-M.Zhu et al.//Leukemia.-1995.-Vol.9.-P. 131.
- Interleukin 1 gene expression in adult T cell leukemia./Y.Wano, T. Hattori, M. Matsuoka et al.//J Clin Invest .-1987.-Vol.80.-P.911−916.
- Intermediate lymphocytic lymphoma: clinical and pathologic features of a recently characterized subtype of non-Hodgkin's lymphoma./R.Shivdasani, J. Hess, A. Skarin et al.//J Clin Oncol.- 1993.-Vol.11.-P.802−811.
- Intermediate lymphocytic lymphoma: immunophenotypic and cytogenetic findings./D.D.Weisenburger, W.G.Sanger, J.O.Armitage et al.// Blood.- 1987.-Vol.69.-P. 1617−1621.
- International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma./ N Engl J Med.- 1993.-Vol.329.-P.987−994.
- Intraclonal generation of antibody mutations in germinal center./Jacob J., Relsoe G., Rajensky K. et al.// Nature.-1991.-Vol.354.-P.389−392.
- Intravascular lymphomatosis: a clinicopathologic study of 10 cases and assessment of response to chemotherapy./J.A.DiGiuseppe, W.G.Nelson, E.J.Seifter et al.// J Clin Oncol.-1994.-Vol.l2.-P.2573−2579.
- Involvement of the Bcl-2 gene in human follicular lymphoma./Y.Tsujimoto, J. Cossman, E. Jaffe et al.// Science.- 1985.-Vol.228.-P. 1440−1443.
- Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis./A.Haimovitz-Friedman, C-C.Kan, D. Ehleiter et al.// J Exp Med.-1994.-Vol.180.-P.525.
- Malignant lymphoma of mucosal associated lymphoid tissue. A distinct B cell lymphoma./P.Isaacson, D. Wright//Cancer.- 1983.-Vol.52.-P.1410.
- Isaacson P.G. Multiple lymphomatous polyposis of the gastrointestinal tract./P.G.Isaacson, K.A.MacLennan, S.G.Subbuswamy// Histopathology.-1984.-Vol.8.-P.641−656.
- ISCN. An international system for human cytogenetic nomenclature. Basel, Switzerland./ Cytogenet Cell Genet 1985.
- Jaffe E.S. Classification of T-cell and NK-cell neoplasms based on the REAL classification./E.S.Jaffe, L. Krenacs, M. Raffeld//Ann Oncol .-1997.-Vol.8.-Suppl 2.-P. 17−24.
- Jaffe E.S. Classification of natural killer (NK) cell and NK-like T-cell malignancies ./E. S. Jaffe//B lood.-1996.-Vol.87.-P. 1207−1210.
- Jaffe E.S. Anaplastic large cell lymphoma: the shifting of diagnostic hematopathology./Jaffe E.S.//Mod Pathol.-2001.-Vol.l4.-P.219−228.
- Jaffe E.S. The role of immunophenotypic markers in the classification of non Hodgkin s lymphomas./ E.S. Jaffe//Semin Oncol.-1990.-Vol. 17.-P.786−791.
- Johnstone R.W. Apoptosis: a link between cancer genetics and chemotherapy. /R.W.Johnstone, A.A.Ruefli, S.W.Lowe//Cell.-2002, Jan 25.-Vol. 108(2).-P. 153−164.
- Apoptosis: a link between cancer genetics and chemotherapy. /R.W.Johnstone, A.A.Ruefli, S.W.Lowe //Cell.-2002 Jan 25.-Vol.l08(2).-P.153−164.
- Kadin M. The t (2−5) in human lymphomas./ M. Kadin, S. Morris// Leuk Lymphoma.- 1998.-Vol.29.-P.249−256.
- Kastan M. On the TRAIL from p53 to apoptosis?/M.Kastan//Nat Genet.-1997,-Vol. 17.-P. 130−131.
- Kaufmann S. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: A cautionary note./S.Kaufmann// Cancer Res.-1989.- Vol.49.-P.5870.
- Kelekar A, Thompson CB. Bcl-2-family proteinsthe role of the BID domain in apoptosis./A.Kelekar, C.B.Thompson// Trends Cell Biol.- 1998.-Vol.8.-P.324−330.
- KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene./G.S.Wu, T.F.Burns, E.R.McDonald et al.// Nat Genet.- 1997.-Vol.17.-P.141−143.
- Kipps TJ. The CD B cell./T.J.Kipps// Adv Immunol.-1989.-Vol. 47.-P.l 17−185.
- Klasa R.J. Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma./R.J.Klasa//Oncology (Williston Pare.).- 2004, Nov.-Vol.l8.-№ 13 (Suppl 10).-P.25−31.
- Klimo P. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma./P.Klimo, J. Connors//Ann Intern Med.- 1985.-Vol.l02.-P.596−602.
- Korsmeyer S. Bcl-2 initiates a new category of oncogenes: regulators of cell death./S .Korsmeyer//Blood.- 1992.-Vol.80.-P.879−886.
- Krammer P.H. CD95's deadly mission in the immune system. /P.H.Krammer// Nature.- 2000.-Vol.407.-P.789−795.
- Kroemer G. Mitochondrial control of cell death./G.Kroemer, J.C.Reed// Nature Med.- 2000.-Vol.6.-P.513−519.
- Lack of correlation between P-glycoprotein and chemotherapy resistance in nasal NK/T-cell lymphomas./G.E.Kim, W.I.Yang, S.W.Lee et al.//Leuk Lymphoma.- 2004, Sep.-Vol.45(9)/-P. 1857−1864.
- Laparotomy staged I an II non-Hodgkin's lymphomas: preliminary results of radiotherapy an adjunctive chemotherapy./L.M.Toonkel, L.M.Fuller, J.F.Gamble et al.//Cancer.- I980.-Vol.45.-P.249−260.
- LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients./C.Bastard, C. Deweindt, J. Kerckaert et al.// Blood.- 1994.-Vol.83.-P.2423−2427.
- Le Beau M. Chromosomal abnormalities in non-Hodgkin's lymphoma./ M. Le Beau //Semin Oncol.- 1990.-Vol.17.-P.20.
- Lethal effect of the anti-Fas antibody in mice./J.Ogasawara, R. Watanabe-Fukunaga, M. Adachi et al.//Nature.- 1993.-Vol.364.-P.806−809.
- Liu Q. High expression of MDR-1 gene and P-glycoprotein in initial and re-biopsy specimens of relapsed B-cell lymphoma./Q.Liu, K. Ohshima, M. Kikuchi//Histopathology.- 2001, Mar.-Vol.38(3).-P.209−216.
- Locksley R.M.The TNF and TNF receptor superfamilies: integrating mammalian biology./R.M.Locksley, N. Killeen, M.J.Lenardo// Cell.- 2001.-Vol. 104.-P.487−501.
- Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma./L.T.Chen, J.T.Lin, J.J.Tai et al.//J Natl Cancer Inst.-2005, Sep.-Vol.21.-№ 97(i8).-P.1345−1353.
- Long-term survival after histologic transformation of low-grade follicular lymphoma./A.Yuen, O. Kamel, J. Halpern et al.//J Clin Oncol.- 1995.-Vol. 13.-P. 1726−1733.
- Lotem J. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor 1 and cancer chemotherapy compounds in myeloid leukemic cells./J.Lotem, L. Sachs //Blood.-1992.-Vol.80.-P.1750.
- Lotem J. Control of sensitivity to induction of apoptosis in myeloid leukemic cells by differentiation and bcl-2 dependent and independent pathways./J.Lotem, L. Sachs //Cell Growth Diff.-1994.-VoI. 5.-P.321.
- Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin’s disease: involvement of apoptosis resistance?/A.A.Brink, J.J.Oudejans, A.J.van den Brule et al.//Mod Phatol.-1998, Apr.-Vol.l l (4).-P.376−383.
- Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia./G.Pozzato, C. Mazzaro, M. Crovatto et al.// Blood.-1994.-Vol.84.-P.3 047−3053.
- Luminari S. Prognosis of follicular lymphomas/ S. Luminari, M. Federico //Hematol Oncol.- 2006, Jun-24.-Vol.2.-P.64−72.376. Lymphoblastic lymphoma in adults./R.Streuli, Y. Kaneko, D. Variakojis et al. // Cancer.- 1981 .-Vol.47.-P.2510−2511.
- Lymphoblastic lymphoma (LBL) and acute lymphoblastic leukaemia (ALL) in adults: relationships and therapeutic perspectives./ G. Santini, A. Congiu, T. D'Amico et al. /Bone Marrow Transplant.-1989 Jan.-Vol.4.- Suppl 1.-P.106−107.
- Lymphocyte homing receptor (CD44) expression is associated with poor prognosis in gastrointestinal lymphoma./H.Joensuu, R. Ristamaki, P. Klemi et al.// Br J Cancer.- 1993.-Vol.68.-P.428−432.
- Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis./R.Watanabe-Fukunaga, C.I.Brannan, N.G.Copeland et al.// Nature.- 1992.-Vol.356.-P.314−317.
- MacLennan I.C. Germinal centers./ MacLennan I.C.//Annu Rev Immunol.-1994.-VoU2.-P.l 17−139.
- MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodkin's lymphoma. Cooperative Study Group./M.Sertoli, G. Santini, T. Chisesi et al.// J Clin Oncol.- 1994.-Vol.l2.-P.1366−1374.A
- Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia./M.Simoyama, K. Ota, M. Kikuchi et al.// J Clin Oncol.-1988.-Vol.6.-P. 1088.
- Malignant angioendotheliomatosis is an angiotropic intravascular lymphoma. Immunohystochemical, ultractructural, and molecular genetics studies./C.Perniciaro, R.K.Wincelmann, M.S.Daoud et al.//Am J Dermatopatol.-1995.-Vol.l7.-P.242−248.
- Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method./R.B.Mann, C.W.Berard//Hematol Oncol.-1983.-Vol. 1.-P. 187−192.
- Mantle cell lymphoma cells express predominantly cyclin Dla isoform and are highly sensitive to selective inhibition of CDK4 kinase activity./M.Marzec, M. Kasprzycka, R. Lai et al.// Blood.- 2006, Sep l.-Vol.l08(5).-P.1744−1750.
- Mantle cell (previously centrocytic) lymphomas express VH genes with nj or very little somatic mutations like the physiologic cell of the follicle mantle./ M. Hummel, J. Tamaru, B. Kalvelage et al.//Blood.-1994.-Vol.84.-403−407.
- Mantle-cell lymphoma: a population-based clinical study./G.Velders, J. Kluin-Nelemans, C. De Boer et al.// J Clin Oncol.- 1996.-Vol.14.-P. 1269−1274.
- Masramon L. Genetic instability and divergence of clonal populations in colon cancer cells in vitro./L.Masramon, E. Vendrell, G. Tarafa et al.//Journal of Cell Science.-2006.-Vol. 119.-P. 1477−1482.
- Mature B-cell lymphoma in children and adolescents: International group pathologist consensus correlates with histology technical quality,/M.A. Lones, M. Raphael, S.L.Perkins et al.//J Pediatr Hematol Oncol.- 2006, Sep.-Vol.28(9).-P.568−574.
- MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis./S.Kondo, G.H.Barnett, H. Hara et al.// Oncogene.-1995.-Vol.10.-P.2001.
- MDR1 and MRP expression in chronic B-cell lymphoproliferative disorders./M.Webb, M. Brun, M. McNiven et al.//Br J Haematol.-1998, Aug.-Vol.l02(3).-P.710−707.
- MDRl/P-glycoprotein in haematological neoplasms. /J.P.Marie, D.C.Zhou, S. Gurbuxani et al.//Eur J Cancar.- 1996 Jun.-Vol.32A (6).-P.1034−1038.
- Mediastinal large cell lymphoma: an uncommon subset of adult lymphoma curable with combined modality therapy./J.Jacobson, A. Aisenberg, L. Lamarre et al.// Cancer.- 1988.-Vol.62.-P. 1893−1898.
- MIP-1 alpha expression in tissues from patients with hemophagocytic syndrome./J.Teruya-Feldstein, J. Setsuda, X. Yao et al.//Lab Invest.-1979.-P.1583−1590.
- Miyashita T. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line./T.Miyashita, J.C.Reed //Blood.-1993.-Vol.81.-P.151.
- Immunohistochemical expression of the p53, mdm2, p21/Waf-l, Rb, pi6, Ki67, cyclin Dl, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas./P.Kanavaros, M. Bai, K. Stefanaki et al.//Histol Histopathol.-2001, Apr.-Vol.l6(2).-P.377−386.
- Molecular analysis of the t (14−18) chromosomal translocation in malignant lymphomas./L.M.Weiss, R.A.Warnke, J. Sklar et al.//N Engl J Med.- 1987.-Vol.317.-P.l 185−1189.
- Molecular cloning of the chromsomal breakpoint of B cell lymphomas and leukemias with the t (ll-14) chromosome translocation.Af.Tsujimoto, J. Yunis, L. Onorato-Showe et al.//Science.- 1984.-Vol.224.-P.1403.
- Molecular epidemiology of Burkitfs lymphoma from South America: differences in breakpoint location and Epstein-Barr virus association from tumors in other world regions./M.I.Gutierrez, K. Bhatia, B. Diez et al.// Blood.-1992.-Vol.79.-P.3261−3266.
- Moller M.B. Mantle cell lymphoma: prognostic capacity of the Follicular Lymphoma International Prognostic Index/ M.B.Moller, N.T.Pedersen, B.E. Christensen//Brit J Haematol.- 2006, Apr-133.-Vol.l.-P.43−49.
- Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms/Kim SZ, Chow KU, Kukoc-Zivojnov N et all. //Leuk Lymphoma.-2004.- Oct- Vol.45 ,№ 10.-P.2037−2045.
- Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein aminoterminal region./L.Flenghi, B. Bigerna, M. Fizzotti et al.// Am J Pathol.- 1996.-Vol.148.-P. 1543−1555.
- Monocytoid B-cell lymphoma: its evolution and relationship to other low-grade B-cell neoplasms./S.T.Traweek, K. Sheibani, C.D.Winberg et al.// Blood.- 1989.-Vol.73.-P.573−578.
- Morphological aspects of carcinogenesis in the lung./L.Chyczewski, J. Niklinski, E. Chyczewska et al.//Lung Cancer.-2001,Dec.-Vol.34.-Suppl 2.-P.17−25
- Morra E. The biological markers of non-Hodgkin's lymphomas: their role in diagnosis, prognostic assessment and therapeutic strategy./E.Morra E//Int J Biol Markers.-1999, Jul-Sep.-Vol.l4(3).-P.149−153.
- Morrison V. Combination chemotherapy in the treatment of follicualr low-grade lymphoma./V.Morrison, B. Peterson// Leuk Lymphoma.- 1993.-Vol. 10.-P.29−33.
- Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed./C.Thieblemont, F. Berger, C. Dumontet et al.// Blood.- 2000.-Vol.95.-P.802−806.
- Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial./A.Aviles, M.J.Nambo, N. Neri et al.//Med Oncol.- 2005.-Vol.22(l).-P.57−62.
- Mucosa-associated lymphoid tissue gastrointestinal and non-gastrointestinal lymphoma behavior: analysis of 108 patients./C.Thieblemont, Y. Bastion, F. Berger et al.// J Clin Oncol.- 1997.-Vol.15.-P. 1624−1630.
- Multidrug resistance in Lactococcus lactis: evidence for ATP-dependent drug extrusion from the inner leaflet of the cytoplasmic membrane./H.Bolhuis, H.W.van Veen, D. Molenaar et al.// EMBO J.-1996.-Vol.l5.-P.4239−4245.
- Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia./P.A.W.Te Boekhorst, B. Lowenberg, J. van Kapel et al.// Leukemia.- 1995.-Vol.9.-P. 1025−1031.
- Nagata S. Apoptosis by death factor./S.Nagata//Cell.- 1997.-Vol.88.-P.355−365.
- Naresh K.N. Distribution of various subtypes of non-Hodgkin's lymphoma in India: a study of 2773 lymphomas using R.E.A.L. and WHO Classifications./K.N.Naresh, V. Srinivas, C.S.Soman//Ann Oncol.- 2000.-Vol.l-Suppl 1.-P.63−67.
- Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus./P.Kanavaros, M. Lescs, J. Briere et al.// Blood.-1993 .-Vol.81 .-P.2688−2695.
- NFkB signals induce the expression of c-FLIP./O.Micheau, S. Lens, O. Gaide et al.// Mol Cell Biol.- 2001.-Vol.21.-P.5299−5305.
- NFkB-mediated up-regulation of bcl-x and bfl-l/al is required for CD40 survival signaling in B lymphocytes./H.H.Lee, H. Dadgostar, Q. Cheng et al.// Proc Natl Acad Sci U S A.- 1999.-Vol.96.-P.9136−9141.
- Nicolson G.L. Prognostic factor and clonal selection./G.L.Nicolson, M. Tubiana //Radiotherapy and Oncol.-1986.-Vol.6(3).-P.167−184.
- Niitsu N. A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma./N.Niitsu, K. Sasaki, M. Umeda// Leukemia.- 1999.-Vol. 13 .-P. 1434−1440.
- NMR structure of the death domain of the p75 neurotrophin receptor./E.Liepinsh, L.L.Ilag, G. Otting G et al.// EMBO J.- 1997.-Vol.16.-P.4999−5005.
- Nodal monocytoid B-cell lymphoma (nodal marginal-zone B-cell lymphoma) ,/B.Nathwani, M. Drachenberg, A. Hernandez et al.// Semin Hematol.-1999.-Vol.36.-P. 128−138.
- Nodular lymphoma-evidence for origin from follicular B lymphocytes. /E.S.Jaffe, E.M.Shevach, M.M.Frank et al.// N Engl J Med.- 1974.-Vol.290.-P.813−819.
- Nodular mixed lymphocytic-histiocytic lymphoma (NM): response and survival. Eastern Cooperative Oncology Group./E.Z.Ezdinli, W.G.Costello, F. Icli et al.// Cancer.- 1980.-Vol.45.-P.261−267.
- Nodular histiocytic lymphoma: factors influencing prognosis and implications for aggressive chemotherapy./J.Glick, E. McFadden, W. Costello et al.// Cancer.- 1982.-Vol.49.-P.840.
- Non-endemic Burkitts lymphoma. A B cell tumor related to germinal centers./R.B.Mann, E.S.Jaffe, R.C. Braylen et al.// N Engl J Med.- 1976.-Vol.295.-P.685−691.
- Nongastric Marginal-Zone B-Cell MALT Lymphoma: Prognostic Value of Disease Dissemination./L. Arcainia, S. Burcheria, A. Rossib et al.//The Oncologist.- 2006, Mar.- Vol.1 l.-№ 3.-P.285−291.
- Nonhepatosplenic gamma-delta T-cell Lymphomas susset of cytotoxic lymphomas with mucosal or skin localisation./B.Arnulf, C. Copie-Bergman, M.N.Larue et al.//Blood.-1998.-Vol.91 .-P. 1723−1731.
- Non-Hodgkin's lymphomas in Greece according to the WHO classification of lymphoid neoplasms. A retrospective analysis of 810 cases./T.Economopoulos, S. Papageorgiou, M.A.Dimopoulos et al.//Acta Haematol.- 2005.-Vol.l 13(2).-P.97−103.
- Nonnasal lymphoma expressing the natural killer cell marcer CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm./J.K.Chan, V.C.Sin, K.F.Wong et al.//Blood.-1997.-Vol.89.-P.4501−4513.
- Non-random chromosome abnormalities in lymphoma./C.Bloomfield, D. Arthur, G. Frizzrera et al.// Cancer Res.- 1983.-Vol.43.-P.2975.
- Intrinsic apoptotic pathway in anaplastic large cell lymphoma./M.P.Oyarzo, E. Drakos, C. Atwell et al.//Hum Pathol.- 2006, Jul.-Vol.37(7).-P.874−882.
- Ong ST, Le Beau MM. Chromosomal abnormalities and molecular genetics of non-Hodgkin's lymphoma./S.T.Ong, M.M.Le Beau// Semin Oncol.-1998.-Vol.25.-P.447−460.
- Ongoing immunoglobulin gene mutations in mantle cell lymphomas./M.Q.Du, T.C.Diss, C.F.Xu et al.// Br J Haematol.-1997.-Vol.96.-P.124−131.
- Overexpression of a M 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance./R.J.Scheper, H.J.Broxterman, G.L.Scheffer et al.// Cancer Research.- 1993.-Vol.53.-P. 1475−1479.
- P53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis./I.Cordone, S. Masi, F.R.Mauro et al.//Blood.-1998.-Vol.91.-P.4342−4349.
- P53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome./E.Pescarmona, P. Pignoloni, M. Puopolo et al.//J Pathol.-2001, Oct.-Vol.l95(3).-P.361−366.
- Pan G. Activation of caspases triggered by cytochrome c in vitro./G.Pan, E.W.Humke, V.M.Dixit//FEBS Lett.- 1998.-Vol.426.-P. 151−154.
- Panayiotidis P. Genetics of small lymphocyte disorders./P.Panayiotidis, P. Kotsi// Semin Hematol.- 1999.-Vol.36.-P. 171−177.
- Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center./P.Johnson, A. Rohatiner, J. Whelan et al.// J Clin Oncol.-1995 .-Vol. 13 .-P. 140−147.
- Pediatric non-Hodgkin lymphomas./N.Brousse, V. Vasiliu, J. Michon et al. //Ann Phatol.- 2004, Dec.-Vol.24(6).-P.574−586.
- Peripheral T/NK -cell lymphoma: a report of the IXth Workshop of the European Assotiation for Haematopthlogy Conference report./ P.M.Kluin, A. Feller, P. Gaulard et al./Histopathlogy.-2001.-Vol.38.-P.250−270.
- Perkins S.L. Work-up and diagnosis of pediatric non-Hodgkin's lymphomas./ S.L.Perkins//Pediatr Dev Phatol.- 2000, Jul-Aug.-Vol.3(4).-P.374−390.
- P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells/M.Michieli, D. Damiani, A. Ermacora et al.//Br J Haematol.- 1997, Feb.-Vol.96(2).-P.356−365.
- Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma./T.E.Witzig, C.A.White, G.A.Wiseman et al.// J Clin Oncol.- 1999.-Vol. 17.-P.3 793−3803.
- Pivotal study of iodine 1−131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas./ M.S.Kaminski, A.D.Zelenetz, O.W.Press et al.// J Clin Oncol.- 2001.-Vol. 19.-P.3918−3928.
- Poor prognosis of mediastinal non-Hodgkin's lymphona with an immature phenotype of CD2+, Cd7 (orCD5)+, CD3-, CD4-, and CD8-./K.Yumura-Yagi, S. Ishihara, J. Hara et al.// Cancer.-1989.-Vol.63.-P.671−674.
- PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma./ C.L.Rosenberg, E. Wong, E.M.Petti et al.//Proc Natl Acad Sci USA.-1991 .-Vol.88.-P.9638−9642.
- Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells./S.S.Dave, G. Wright, B. Tan et al.//New En J Med.-2005.-Vol.351 .-№ 21 .-P.2170−2178.
- Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma./ S. Ansell, T. Habermann, P. Kurtin et al.// J Clin Oncol.- 1997.-Vol.l5.-P.2296−2301.
- Primary cutaneous follicle center cell lymphoma with follicular growth pattern./L.Cerroni, E. Arzberger, B. Putz et al.// Blood.- 2000.-Vol.95.-P.3922−3928.
- Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome C./S.J.Korsmeyer, M.C.Wei, M. Saito et al.// Cell Death Differ.- 2000.-Vol.7.-P.l 166−1173.
- Prognosis of follicular lymphoma, a predictive model based on a retrospective analysis of 987 cases./M.Federico, U. Vitolo, P. Zinzani et al.// Blood.- 2000.-Vol.95.-P.783−789.
- Van Krieken J.H.Splenic margimal zone lymphocites and related cell in the lymph node: a morphologic and immunohistochemical study./Van Krieken J.H., C. von Schilling, P.M.Kluin et al.//Hum Pathol.-1989.-Vjl.20.-P.320−325.
- Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma./R.D.Gascoyne, P. Aoun, D. Wu et al.// Blood.- 1999.-Vol.93.P.3913−3921.
- Prognostic implications of karyotype and morphology in patients with non-Hodgkin's lymphoma./Y.Kaneko, J. Rowley, D. Variakojis et al.// Int J Cancer.-1983.-Vol.32.-P.683.
- Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma./S.K.Sohn, J.T.Jung, D.H.Kim et al.//Am J Hematol.- 2003, Jun.-Vol.73(2).-P. 101 -107.
- Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas./A.Zhang, K. Ohshima, K. Sato et al.//Pathol Int.-1999, Dec.-Vol.49(12).-P. 1043−1052.
- Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma./G.W.van Imhoff, E.J.Boerma, B. van der Holt et al.//J Clin Oncol.- 2006, Sep l.-Vol.24(25).-P.4135−4142.
- Prognostic implications of ploidy and proliferative activity in diffuse large cell lymphomas./K.Bauer, D. Merkel, J. Winter et al.// Cancer Res.- 1986.-Vol.46.-P.3173−3178.
- Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems./ G. Pereal, A. Altes, S. Montoto et al.//Annals of Oncology.-2005 .-Vol. 16(9).-P. 1508−1513.
- Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma./O.Hermine, C. Haioun, E. Lepage et al.//Blood.-1996.-Vol.87.-P.265.
- Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study./J.N.Winter, E.A.Weller, S.J.Homing et al.//Blood.-2006,Jun 1.-Vol. 107(1 l).-P.4207−4213.
- Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma./M.Llanos, H. Alvarez-Arguelles, R. Aleman et al.//Med Oncol.-2001.-Vol. 18(1).-P. 15−22.
- Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma./S.K.Sohn, J.T.Jung, D.H.Kim et al.//Am J Hematol.- 2003, Jun.-Vol.73(2).-P. 101 -107.
- Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma./H.Preti, F. Cabanillas, M. Talpaz et al.// Ann Intern Med.- 1997,-Vol.127.-P. 186−194.
- Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation./N.Kyprianou, H.F.English, N.E.Davidson et al.// Cancer Res.-1991 .-Vol.51 .-P. 162.
- Protection from fas-mediated apoptosis by a soluble form of the fas molecule./J.Cheng, T. Zhou, C. Liu et al.// Science.- 1994.-Vol.263.-P. 1759−1762.
- Protein expression of bax, bcl-2, and p53 in patients with non-Hodgkin's gastric lymphoma: prognostic significance./G.K.Charalambous, I.P.Gomatos, M.M.Konstadoulakis et al.//World J Surg.-2000 May.-Vol.24(5).-P.608−614,
- Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma./C.Gulmann, Espina V, Petricoin E et al.//Clin Cancer Res.-2005, Aug 15,-Vol.l 1(16).-P.5847−5855.
- Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation./V. Weller, U. Malipiero,
- A.Aguzzi et al.//J Clin Invest.-1995.-Vol.95.-P.2633.
- Radaszkiewicz T. Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis./T.Radaszkiewicz,
- B.Dragosics, P. Bauer P.//Gastroenterology.- 1992.-Vol.l02.-P.1628−1638.
- Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma./R.Meyer, G. Browman, M. Samosh et al.//J Clin Oncol.- 1995.-Vol.l3.-P.2386−2393.
- Raptis S. Genetic instability in human tumors./S.Raptis, B. Bapat//EXS.-2006.-Vol.96.-P.303−320.482. RB regulates the stability and the apoptotic function of p53 via MDM2./J-K Hsieh, F. Chan, D. O'Connor et al.// Mol Cell.- 1999.-Vol.3.-P.181−193.
- Reed J.C. Dysregulation of apoptosis in cancer/ J.C.Reed// Cancer J Sci Am.- 1998.-Vol.4.-P.8−13.
- Reed J.C. Mechanisms of Bcl-2 family protein function and dysfunction in health and disease./J.C.Reed// Behring Inst Mitt.- 1996.-Vol.97.-P.72−100.
- Regulation of leukocyte adhesion molecule-1 (TQ1, Leu-8) expression and shedding by normal and malignant cells./O.Spertini, A.S.Freedman, M.P.Belvin et al.// Leukemia.-199 l.-Vol.5.-P.300−308.
- Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group/ B.D.Cheson, S.J.Horning, Coiffier B. et all. // J Clin Oncol.- 2000 Jun-18.-Vol.l 1.-P.2351−2360.
- Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia./H.M.Kantarjian, S. O'Brien, T.L.Smith et al.// J Clin Oncol.- 2000.-Vol.18.-P.547−561.
- Results of radiotherapy in control of stage I and II non-Hodgkin's lymphoma.//M.G.Chen, L.R.Prosnitz, A. Gonzalez-Serva et al.//Cancer.- 1979.-Vol.43 .-P. 1245−1254.
- Richter’s syndrome: a report on 39 patients./ L. Robertson, W. Pugh, S. O'Brien et al. .// J Clin Oncol.- 1993.-Vol.l 1.-P.1985−1989.
- RIP: A novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death./B.Z.Stanger, P. Leder, T-H.Lee et al.// Cell.- 1995.-Vol.81.-P.513−523.
- Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-Jear suvival data./W.S.Velasgues, S. Lagannath, S.L.Tucker et al.// Blood.-1989.-Vol.74(2).-P.551−557.
- Risk factors for treatment-related in elderly patients with aggressive non-Hodgkin's lymphoma: results in of a multivariate analysis./H.Gomez, M. Hidalgo, L. Casanova et al.//J Clin Oncol.- 1998.-Vol.l6.-P.2065−2069.
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program./P.McLaughlin, A. Grillo-Lopez, B. Link et al.// J Clin Oncol.- 1998.-Vol.l6.-P.2825−2833.
- Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study./B.Coiffier, C. Haioun, N. Ketterer et al.//Blood.- 1998.-Vol.92.-P.1927−1932.
- Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival./O.M.Howard, J.G.Gribben, D.S.Neuberg et al.// J Clin Oncol.- 2002.-Vol.20.-P. 1288−1294.
- Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment./T.A.Davis, A.J.Grillo-Lopez, C.A.White et al.// J Clin Oncol.- 2000.-Vol.l8.-P.3135−3143.
- Rowley J.D. Chromosome studies in the non-Hodgkin's lymphomas: the role of the 14- 18 translocation./J.D.Rowley //J Clin Oncol.-1988.-Vol.6.-P.919−925.
- Rubin H. Clonal selection versus genetic instability as the driving force in neoplastic transformation./H.Rubin//Adv Cancer Res.- 2001.-Vol.83.-P.l 59−207.
- Rui L. Lymphoma and the control of B cell growth and differentiation./L.Rui, C.C. Goodnow//Curr Mol Med.- 2006, May.-Vol.6(3).-P.291−308.
- Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo./K.Blyth, F. Vaillant, L. Hanlon et al.//Cancer Res.- 2006, Feb 15.-Vol.66(4).-P.2195−2201.
- Syndromes with genetic instability: Model diseases for (skin) cancerogenesis./S.Emmert, D. Leibeling, T.M.Runger//J Dtsch Dermatol Ges.-2006, Sep.-Vol.4(9).-P.721−731.
- Salmon S.E. Multidrug-resistant myeloma: Laboratory and clinical effects of verapamil as a chemosensitizer./S.E.Salmon, W.S.Dalton, T.M.Grogan// Blood.- 1991.-Vol.78.-P.44−50.
- Salven P. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma./P.Salven, L. Teerenhovi, H. Joensuu// Blood.- 1999.-Vol.94.-P.3334−3339.
- Schein P. Bleomycin, Adriamycin, cyclophosphamide, vincristine and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma./P.Schein, V. DeVita, S. Hubbard //Ann Intern Med.-1976.-Vol.85.-P.417.
- Sen S. Apoptosis: Biochemical events and relevance to cancer chemotherapy. /S.Sen, M. D'Incalci// FEBS Lett.-1992.-Vol.307-P. 122.
- Serum nm23-Hl protein as a prognostic factor for indolent non-Hodgkin's lymphoma./N.Niitsu, M. Okamoto, J. Okabe-Kado et al.// Leukemia.- 2001.-Vol.l5.-P.832−839.
- Singer C. RJ Clinical studies of ABMT in non-Hodgkin-s lymphoma./ C.R.J.Singer, A.H.Goldstone//Clin Haematol.- 1985.-Vol.l5.-P.105−149.
- Sites of specific B-cell activation in primary and secondary responses to T cell-dependent and T cell independent antigens./Y.J.Liu, J. Zhang, P.J.Lane et al.//Eur J Immunol.-1991 .-Vol.21 .-P.2951 -2962.
- Slapak C.A. Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells./C.A.Slapak, N. Mizunuma, D.W.Kufe// Blood.-1994.-Vol.84.-P.3113−3121.
- Small lymphocytic lymphoma: a clinicophathologic analysis of 268 cases./J.Ben-Ezra, J.S.Burke, W.G.Swartz et al.// Blood.-1989.-Vol.73.-P.579−587.
- Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols./C.Soussain, C. Patte, M. Ostronoff et al.// Blood.-1995.-Vol.85.-P.664−674.
- Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity./K.Gronbaek, P.T.Straten, E. Ralfkiaer et al.// Blood.- 1998.-Vol.92.-P.3 018−3024.
- Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype./N.Rampino, H. Yamamoto, Y. Ionov et al.// Science.- 1997.-Vol.275.-P.967−969.
- Sonneveld P. Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia./P.Sonneveld, K. Nooter K.// British Journal of Haematology.- 1990.-Vol.75.-P.208−210.
- Sonneveld P. Clinical modulation of multidrug resistance in multiple myeloma.// P. Sonneveld, M. De Schoester, K.Leeuw.// Journal of Clinical Oncology.- 1994.-Vol. 12.-P. 1584−1591.
- Sonneveld P. Multidrug resistance in haematological malignancies /P. Sonneveld //J Int Med.-2000, May. Vol. 247.- P.521−532
- Soslow R. B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology./R.Soslow, R. Baergen, R. Warnke// Cancer.- 1999.-Vol.85.-P.2648−2654.
- Splenic marginal zone lymphoma: a prognostic model for clinical use ./L.Arcaini, M. Lazzarino, N. Colombo et al.//Blood.-2006, June.-Vol.l07.-№ 12.-P.4643−4649.
- Spontaneous regression of non-Hodgkin's lymphoma: a report of nine cases. /J.G.Krikorian, C.S.Portlock, P. Cooney et al.// Cancer.- 1980.-Vol.46.-P.2093−2099.
- Spontaneous apoptosis of Reed-Sternberg and Hodgkin cells- clinical and pathological implications in patients with Hodgkin’s disease./P.Smolewski, H. Niewiadomska, E. Los et al.//Int J Oncol.- 2000, Sep.-Vol.l7(3).-P.603−609.
- Stage III follicular lymphoma: durable remissions with a combined chemotherapy-radiotherapy regimen./P.McLaughlin, L.M.Fuller, W.S.Velasquez et al.// J Clin Oncol.- 1987.-Vol.5.-P.867−874.
- Stage I-II follicular lymphoma. Treatment results for 76 patients./P.McLaughlin, L.M.Fuller, W.S.Velasquez et al.// Cancer.- 1986.-Vol.58.-P. 1596−1602.
- Study of the immunohistochemistry and T-cell clonality of enteropathy-associated T-cell lymphoma./A.Murray, E. Cuevas, D. Jones et al.//Am J Pathol.-1995.-Vol.146.-P.509−519.
- Subcutaneous panniculitic T-cell lyphoma is a tumor of cytotoxic T lymphocytes./S.Kumar, L. Krenacs, J. Medeiros et al.//Hum Pathol .-1998.-Vol.29.-P.397−403.
- Superiority of ProMACE-CytaBOM Over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial./D.Longo, V. DeVita, P. Duffey et al.// J Clin Oncol.- 1991.-Vol.9.-P.25−38.
- Surcek M. Immunohistochemistry and genotype analysis of tumors. First part: Which future for the immunochemical diagnosis of cancer?/M.Surcek, J.C.Sabourin//Ann Pathol.- 2002, Apr.-Vol.22(2).-P. 102−112.
- Survival after relapse of low-grade non-Hodgkin's lymphoma. Implications for marrow transplantation./D.Weisdorf, J. Andersen, J. Glick et al.// J Clin Oncol.- 1992.-Vol. 10.-P.942−947.
- Tan B. Multidrug resistance transporters and modulation./B.Tan, D. Piwnica-Worms, L. Ratner //Curr Opin Oncol.- 2000, Sep.-Vol.l2(5).-P.450−458.
- T-cell lymphoma involving subcutaneous tissue: a clinicopathologic entity commonly associated with hemophagocytic syndrome./C.Gonzalez, L. Medeiros, R. Braziel R et al.// Am J Surg Pathol.- 1991.-Vol. 15.-P. 17−27.
- T-cell lymphomas. Immunologic, histologic, clinical, and therapeutic analysis of 63 cases./B.Coiffier, F. Berger, P-A.Bryon et al.// J Clin Oncol.- 1988.-V0I.6.-P. 1584−1589.
- T-cell/histiocyte-rich large B-cell lymphoma: a heterogeneous entity with derivation from germinal center B cells./ M.S.Lim,
- M.Beaty, L. Sorbara et al.//Am J Surg Pathol./- 2002, Nov.-Vol.26(ll).-P.1458−1466.
- T-cell-rich B large-cell lymphoma simulating lymphocyte-rich Hodgkin’s disease./J.A.McBride, J. Rodriguez, R. Luthra R. et al.// Am J Surg Pathol.- 1996.-Vol.20.-193−201.
- The aberrancy of immunophenotype and immunoglobulin status as indicators of prognosis in B cell diffuse large cell lymphoma./C.M.Spier, T.M.Grogan, S.M.Lippman et al.//Am J Pathol.- 1988.-Vol.l33.-P.l 18−126.
- The Fas counterattack In vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma./M.Bennett, J. O'Connell, O’sullivan et al.// J Immunol.- 1998.-Vol.160.-P.5669−5675.
- The gastric marginal zone B-cell lymphoma of MALT type./E.Zucca, F. Bertoni, E. Roggero et al.// Blood.- 2000.-Vol.96.-P.410−419.
- The histopathology of splenic lymphoma with villous lymphocytes./ P.G.Isaacson, E. Matutes, M. Burke et al.// Blood.-1994.-Vol.84.-P.3828−3834.
- The human gut contains a novel population of B lymphocytes which resemble marginal zone cells./J.Spencer, T. Finn, K.A.Pulford et al.//Clin Exp Immunol.-1985.-Vol.62.-P.607−612.
- The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders./E.Matutes, R. Morilla, K. Owusu-Ankomah et al.// Blood.-1994.-Vol.83.-P.1558−1562.
- The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group./J.Blay, F. Gomez, C. Sebban et al.// Blood.- 1998.-Vol.92.-P.3562−3568.
- The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma./ Blood.- 1997.-Vol.89.-P.3909−3918.
- The role of apoptosis in the response of cells and tumours to mild hyperthermia./B.V.Harmon, Y.S.Takano, C.M.Winterford et al.// Int J Radiat Biol.-1991.-Vol.59.-P.489.
- Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial./C.Guglielmi, F. Gomez, T. Philip et al.//J Clin Oncol.- 1998.-Vol.l6.-P.3264−3269.
- Tomei L.D. Inhibition of radiation-induced apoptosis in vitro by tumor promoters./L.D.Tomei, P. Kanter, C.E.Werner// Biochem Biophys Res Commun.-1988.-Vol.155.-P.324.
- Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes./P.R.Walker, C. Smith, T. Youdale et al.// Cancer Res.- 1991.-Vol.51.-P.1078.
- Translocation (11- 14): a cytogenetic anomaly associated with B-cell lymphomas of non-follicle centre cell lineage.-E.Vandenberghe, C. Wolf-Peeters, van den OJ. et al.//J Patol.-1991.-Vol.l63.-P.13−18.
- Treatment of lymphoblastic lymphoma in Adults./C.Coleman, V.Jr.Picozzi, R. Cox et al.// J Clin Oncol.- 1986.-Vol.4.-P.1628.
- Tumoricidal activity in the absence of hepatocyte cytotoxicity of a novel anti-human DR5 monoclonal antibody./K.Ichikawa, W. Liu, Z. Wang et al.// Nat Med.- 2001 .-Vol.7.-P.954−960.
- Tumors of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumors (WHO OMS)./Jaffe E.S., N.L.Harris, H. Stein, J.W.Vardiman.-Lyon: IARS-Press, 2001.- 350 p.
- Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer./M.C.Southey, M.A.Jenkins, L. Mead et al.//J Clin 0ncol.-2005, Sep 20.-Vol.23(27).-P.6524−6532.
- Variant translocations in sporadic Burkitf s lymphoma detected in fresh tumor material: analysis of three cases./G.Cario, U.Z.Stadt, A. Reiter et al.// Br J Haematol.-2000.-Vol.l 10.-P.537−546.
- Voutsinas G. Mutagenesis, apoptosis, basic relation to carcinogenic models./G.Voutsinas//Folia Histochem Cytobiol.- 2001.-Vol.39.- Suppl 2.-Vol.56−57.
- Warnke R.A. Tumor Progression in malignant lymphomas./R.A. Warnke//Bull Cancer.-1991 .-Vol.78(2).-P. 181−186.
- What should be the morphologic criteria for the subdivision of follicular lymphomas?/B .N.Nathwani, G .E .Metter, T. P .Miller et al.//Blood.-1986.-Vol.68.~ P.837−845.
- Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression./L.B.Owen-Schaub, W. Zhang, J.C.Cusack et al.// Mol Cell Biol.- 1995 .-Vol. 15 .-P.3032−3040.
- Williams M.E. Genotypic characterization of centrocytic lymphoma: frequent rearragement of the chromosome 11 bcl-1 locus./M.E. Williams, C.D.Westermann, S.H.Swerdlow// Blood.-1990.-Vol.76.-P.1387−1391.
- Yang X. Essential role of CED-4 oligomerization in CED-3 activation and apoptosis./X.Yang, H. Chang, D. Baltimore// Science.- 1998.-Vol.281.-P.1355−1357.
- Yao K-S. Apoptosis in human adenocarcinoma HT29 cells induced by exposure to hypoxia./K-S.Yao, M. Clayton, P.J.J.O'Dwyer// Natl Cancer.- 1995 .-Inst 87.-P.117.
- Yunis J. Bcl-2 oncogene rearrangement in follicular and diffuse large-cell and mixed-cell lymphoma./J.Yunis// Cancer Cells.- 1989.-Vol.7.-P.37−40.
- Zhou M. Analysis of the non-Hodgkin lymphoma’s clinic and blood marrow cytogenetics./M.Zhou, L. Cen, Y. Xue//Z X Xue Za Zhy.- 2006, Oct.-Vol.23(5).-P.568−570.
- Иммуноцитохимическая реакция (объяснение в тексте)1. РЧ1. Микрофото 1.
- Позитивный контроль С045 (общелейкоцитарный антиген) (метка с щелочной фосфатазой, хЮО).
- Микрофото 3. Гликофорин, А на эритроцитах, опухолевая клетка -негативна1. Микрофото 5.
- Опухолевая клетка (мазки крови, окраска по Романовскому) (х 100)1. Микрофото 2.1. Негативный контроль пан пито кераги н (эпител нал ьн ыйантиген) (х 100).